[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 825
1. Mote PA, Arnett-Mansfield RL, Gava N, deFazio A, Mulac-Jericevic B, Conneely OM, Clarke CL: Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology; 2006 Dec;147(12):5503-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the uterus, PRA was not detected in luminal epithelium at any stage of the cycle, and PR+ luminal cells expressed only PRB.
  • This study has shown that nonoverlapping PRA and PRB expression in the uterus, in particular the lack of PRA, and expression of PRB only in the luminal epithelium throughout the estrous cycle, is likely to contribute to the distinct roles of PRA and PRB in the adult mouse.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endocrinology. 2006 Dec;147(12):5501-2 [17107971.001]
  • (PMID = 16980438.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD32007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B
  •  go-up   go-down


2. Hwang JC, Wang CT, Chien CC: Effect of climatic temperature on fluid gain in hemodialysis patients with different degrees of overhydration. Blood Purif; 2007;25(5-6):473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To assess the effect of seasonal temperature on the interdialytic body weight gain (deltaBW), %deltaBW/dry weight (DW), and pre-dialysis blood pressure in chronic hemodialysis (HD) patients with different degrees of overhydration.
  • A total of 221 end-stage renal disease patients treated with HD at our center throughout the year 2005 were enrolled.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Climate. Diabetes Mellitus / therapy. Female. Hemodialysis Solutions / chemistry. Humans. Male. Middle Aged. Taiwan. Weather

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • [CommentIn] Blood Purif. 2008;26(5):404-6 [18594140.001]
  • (PMID = 18075248.001).
  • [ISSN] 1421-9735
  • [Journal-full-title] Blood purification
  • [ISO-abbreviation] Blood Purif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hemodialysis Solutions
  •  go-up   go-down


3. Makhsous M, Lin F, Knaus E, Zeigler M, Rowles DM, Gittler M, Bankard J, Chen D: Promote pressure ulcer healing in individuals with spinal cord injury using an individualized cyclic pressure-relief protocol. Adv Skin Wound Care; 2009 Nov;22(11):514-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Forty-four subjects, aged 18-79 years, with a Stage II or Stage III PrU, were randomly assigned to the control (n = 22) or treatment (n = 22) groups.

  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1987 Nov;107(5):641-8 [3310792.001]
  • [Cites] Geriatr Nurs. 1989 Jul-Aug;10(4):190-2 [2777121.001]
  • [Cites] J Rehabil Res Dev. 1990 Spring;27(2):141-50 [2366198.001]
  • [Cites] JAMA. 1990 Dec 12;264(22):2905-9 [2232085.001]
  • [Cites] West J Med. 1991 May;154(5):539-44 [1830985.001]
  • [Cites] J Rehabil Res Dev. 1992 Fall;29(4):21-31 [1432724.001]
  • [Cites] JAMA. 1993 Jan 27;269(4):494-7 [8338511.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Sep;74(9):947-53 [8379841.001]
  • [Cites] Arch Phys Med Rehabil. 1994 May;75(5):535-9 [8185445.001]
  • [Cites] Paraplegia. 1995 Mar;33(3):141-7 [7784116.001]
  • [Cites] Ostomy Wound Manage. 1997 Jan-Feb;43(1):28-32, 34-5, 38; quiz 39-40 [9087064.001]
  • [Cites] Ann Intern Med. 1981 May;94(5):661-6 [7235399.001]
  • [Cites] Ostomy Wound Manage. 2004 Oct;50(10):40-2, 44-52; discussion 53 [15509881.001]
  • [Cites] Am J Health Syst Pharm. 2004 Sep 15;61(18):1895-905; quiz 1906-7 [15487879.001]
  • [Cites] Am J Surg. 2004 Jul;188(1A Suppl):9-17 [15223496.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001735 [10796662.001]
  • [Cites] Spinal Cord. 2003 Dec;41(12):692-5 [14639449.001]
  • [Cites] Nurs Manag (Harrow). 2003 Oct;Suppl:6-10, 12-4; quiz 14-5 [14694861.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Apr;82(4):529-33 [11295017.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Dec;56(12):M795-9 [11723157.001]
  • [Cites] Wound Repair Regen. 2001 Sep-Oct;9(5):347-52 [11896977.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2002;36(5):279-83 [12477086.001]
  • [Cites] Surg Technol Int. 2003;11:23-31 [12931279.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):635-41 [14568851.001]
  • [Cites] J Spinal Cord Med. 2007;30(5):497-507 [18092567.001]
  • [Cites] Arch Phys Med Rehabil. 2007 Jul;88(7):862-70 [17601466.001]
  • [Cites] Arch Phys Med Rehabil. 2006 Oct;87(10):1396-402 [17023252.001]
  • [Cites] Adv Skin Wound Care. 2006 Sep;19(7):398-405; quiz 405-7 [16943709.001]
  • [Cites] JAMA. 2006 Aug 23;296(8):974-84 [16926357.001]
  • [Cites] Plast Reconstr Surg. 1998 Sep;102(3):765-72 [9727442.001]
  • [Cites] Adv Wound Care. 1998 Sep;11(5):237-46 [10326341.001]
  • [Cites] Arch Phys Med Rehabil. 1961 Jan;42:19-29 [13753341.001]
  • (PMID = 20026933.001).
  • [ISSN] 1538-8654
  • [Journal-full-title] Advances in skin & wound care
  • [ISO-abbreviation] Adv Skin Wound Care
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844; United States / NICHD NIH HHS / HD / HD047959-01; United States / NICHD NIH HHS / HD / R21 HD046844-01A1; United States / NICHD NIH HHS / HD / HD046844-02; United States / NICHD NIH HHS / HD / R21 HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844-02; United States / NICHD NIH HHS / HD / R41 HD047959; United States / NICHD NIH HHS / HD / R41 HD047959-01; United States / NICHD NIH HHS / HD / HD046844-01A1
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167781; NLM/ PMC2860306
  •  go-up   go-down


Advertisement
4. Eitzen I, Eitzen TJ, Holm I, Snyder-Mackler L, Risberg MA: Anterior cruciate ligament-deficient potential copers and noncopers reveal different isokinetic quadriceps strength profiles in the early stage after injury. Am J Sports Med; 2010 Mar;38(3):586-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior cruciate ligament-deficient potential copers and noncopers reveal different isokinetic quadriceps strength profiles in the early stage after injury.

  • MedlinePlus Health Information. consumer health - Knee Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2000;8(2):76-82 [10795668.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2000;8(5):262-9 [11061293.001]
  • [Cites] Ergonomics. 2000 Oct;43(10):1603-9 [11083140.001]
  • [Cites] J Orthop Sports Phys Ther. 2001 Oct;31(10):546-66 [11665743.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2002 Jan;10(1):10-9 [11819015.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Jan-Feb;57(1):19-24 [12170345.001]
  • [Cites] J Sports Sci. 2002 Sep;20(9):689-96 [12200920.001]
  • [Cites] Int Orthop. 2002;26(6):374-6 [12466872.001]
  • [Cites] J Orthop Res. 2003 Mar;21(2):231-7 [12568953.001]
  • [Cites] Clin Orthop Relat Res. 1990 Jun;(255):204-14 [2347154.001]
  • [Cites] Am J Sports Med. 1990 Jul-Aug;18(4):396-9 [2403189.001]
  • [Cites] Am J Sports Med. 1991 Sep-Oct;19(5):513-8 [1962720.001]
  • [Cites] Clin Sports Med. 2008 Jul;27(3):383-404, vii [18503874.001]
  • [Cites] Clin Sports Med. 2008 Jul;27(3):405-24, vii-ix [18503875.001]
  • [Cites] J Athl Train. 2008 Jul-Aug;43(4):396-408 [18668173.001]
  • [Cites] Arch Phys Med Rehabil. 2008 Dec;89(12):2324-31 [19061745.001]
  • [Cites] Br J Sports Med. 2009 May;43(5):371-6 [19224907.001]
  • [Cites] J Biomech. 2004 Jun;37(6):857-64 [15111073.001]
  • [Cites] Am J Sports Med. 1992 Mar-Apr;20(2):162-8 [1558244.001]
  • [Cites] Am J Sports Med. 1992 Jul-Aug;20(4):471-5 [1415894.001]
  • [Cites] Am J Sports Med. 1992 Nov-Dec;20(6):754-60 [1456372.001]
  • [Cites] Am J Sports Med. 1993 Sep-Oct;21(5):738-43 [8238718.001]
  • [Cites] J Orthop Sports Phys Ther. 1994 Aug;20(2):60-73 [7920603.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 1993;1(3-4):226-34 [8536037.001]
  • [Cites] J Orthop Res. 1995 Nov;13(6):930-5 [8544031.001]
  • [Cites] Int J Sports Med. 1996 Apr;17(3):223-8 [8739578.001]
  • [Cites] Am J Sports Med. 1997 Mar-Apr;25(2):191-5 [9079172.001]
  • [Cites] J Orthop Sports Phys Ther. 1998 Jul;28(1):23-31 [9653687.001]
  • [Cites] Scand J Med Sci Sports. 1998 Oct;8(5 Pt 1):257-64 [9809383.001]
  • [Cites] Med Sci Sports Exerc. 1999 Feb;31(2):210-5 [10063808.001]
  • [Cites] Eur J Appl Physiol. 2005 Oct;95(4):371-6 [16086147.001]
  • [Cites] BMC Musculoskelet Disord. 2006;7:9 [16448576.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jan;454:35-47 [17075382.001]
  • [Cites] Phys Ther. 2007 Mar;87(3):337-49 [17311886.001]
  • [Cites] Arch Phys Med Rehabil. 2007 May;88(5):626-31 [17466732.001]
  • [Cites] J Strength Cond Res. 2007 May;21(2):451-5 [17530951.001]
  • [Cites] J Electromyogr Kinesiol. 2007 Aug;17(4):484-92 [16822681.001]
  • [Cites] Scand J Med Sci Sports. 2007 Dec;17(6):656-61 [17331086.001]
  • [Cites] Am J Sports Med. 2008 Jan;36(1):48-56 [17932399.001]
  • [Cites] Clin Physiol Funct Imaging. 2008 Mar;28(2):113-9 [18070123.001]
  • [Cites] Arthroscopy. 2008 Mar;24(3):276-84 [18308178.001]
  • [Cites] J Athl Train. 2008 Apr-Jun;43(2):144-51 [18345338.001]
  • [Cites] Ann Acad Med Singapore. 2008 Apr;37(4):330-40 [18461219.001]
  • (PMID = 20110458.001).
  • [ISSN] 1552-3365
  • [Journal-full-title] The American journal of sports medicine
  • [ISO-abbreviation] Am J Sports Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD037985-05; United States / NICHD NIH HHS / HD / R01 HD037985-09; United States / NICHD NIH HHS / HD / R01 HD 37985-04; United States / NICHD NIH HHS / HD / HD037985-07S1; United States / NICHD NIH HHS / HD / R01 HD037985-08; United States / NICHD NIH HHS / HD / R01 HD037985-07S1; United States / NICHD NIH HHS / HD / R01 HD037985-06; United States / NICHD NIH HHS / HD / R01 HD037985; United States / NICHD NIH HHS / HD / R01 HD037985-07; United States / NICHD NIH HHS / HD / HD037985-05; United States / NICHD NIH HHS / HD / HD037985-06; United States / NICHD NIH HHS / HD / HD037985-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS315235; NLM/ PMC3158984
  •  go-up   go-down


5. Hinrichsen VL, Klassen AC, Song C, Kulldorff M: Evaluation of the performance of tests for spatial randomness on prostate cancer data. Int J Health Geogr; 2009 Jul 03;8:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The power of several of these tests has been evaluated and compared using simulated data, but their performance using real unadjusted data and data adjusted for individual- and area-level covariates has not been reported previously.We evaluated data on prostate cancer histologic tumor grade and stage of disease at diagnosis for incident cases of prostate cancer reported to the Maryland Cancer Registry during 1992-1997.
  • We chose 3 spatial clustering tests that are commonly used to evaluate the geographic distribution of disease: Cuzick-Edwards' k-NN (k-Nearest Neighbors) test, Moran's I and Tango's MEET (Maximized Excess Events Test).
  • RESULTS: For both grade and stage at diagnosis, we found that Cuzick-Edwards' k-NN and Moran's I were very sensitive to the percent of population parameter selected.
  • For stage at diagnosis, all three tests showed that the models with individual- and area-level adjustments reduced clustering the most, but did not reduce it entirely.
  • CONCLUSION: Based on this specific example, results suggest that these tests provide useful tools for evaluating spatial clustering of disease characteristics, both before and after consideration of covariates.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):705-9 [11333293.001]
  • [Cites] Environ Health. 2009;8:3 [19208254.001]
  • [Cites] Stat Med. 1995 Nov 15-30;14(21-22):2323-34 [8711272.001]
  • [Cites] Am J Epidemiol. 1997 Jul 15;146(2):161-70 [9230778.001]
  • [Cites] Biometrika. 1950 Jun;37(1-2):17-23 [15420245.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):73-80 [15615917.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7881-8 [16204005.001]
  • [Cites] Am J Prev Med. 2006 Feb;30(2 Suppl):S60-6 [16458791.001]
  • [Cites] Am J Prev Med. 2006 Feb;30(2 Suppl):S67-76 [16458792.001]
  • [Cites] Am J Prev Med. 2006 Feb;30(2 Suppl):S77-87 [16458794.001]
  • [Cites] Stat Med. 2006 Mar 15;25(5):825-39 [16453369.001]
  • [Cites] Int J Health Geogr. 2006;5:15 [16608532.001]
  • [Cites] Int J Health Geogr. 2006;5:31 [16884528.001]
  • [Cites] Health Place. 2007 Mar;13(1):152-63 [16406744.001]
  • [Cites] Int J Health Geogr. 2006;5:59 [17176460.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Stat Med. 2007 Mar 30;26(7):1594-607 [16795130.001]
  • [Cites] Ann Epidemiol. 2007 Jul;17(7):520-4 [17448679.001]
  • [Cites] Stat Med. 2008 Apr 30;27(9):1468-89 [17708511.001]
  • [Cites] Int J Health Geogr. 2008;7:28 [18518988.001]
  • [Cites] Stat Med. 2008 Aug 15;27(18):3612-28 [18416442.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):932-6 [19035447.001]
  • [Cites] Prev Med. 2004 Sep;39(3):441-8 [15313082.001]
  • (PMID = 19575788.001).
  • [ISSN] 1476-072X
  • [Journal-full-title] International journal of health geographics
  • [ISO-abbreviation] Int J Health Geogr
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA095979; United States / NICHD NIH HHS / HD / R01 HD048852; United States / NCI NIH HHS / CA / R01CA95979; United States / NICHD NIH HHS / HD / R01HD048852
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2714079
  •  go-up   go-down


6. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF: Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int; 2005 Mar;67(3):1136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Centers for Disease Control and Prevention (CDC) recommends hepatitis B virus (HBV) immunization for all hemodialysis (HD) patients because they are at high risk of infection.
  • Several studies have shown that the development of protective antibody titers after HBV vaccination is much lower in HD patients.
  • We hypothesized that human immunodeficiency virus (HIV) infection in patients with end-stage renal disease (ESRD) would further impair the immune response to hepatitis B vaccination.
  • RESULTS: Of the 347 adult HIV ESRD patients, 116 received three doses of recombinant hepatitis B vaccination.
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Hepatitis B Antibodies / blood. Humans. Male. Middle Aged. Retrospective Studies. Vaccination


7. Takahashi E, Dai G, Wang R, Ohki K, Rosen GD, Galaburda AM, Grant PE, Wedeen VJ: Development of cerebral fiber pathways in cats revealed by diffusion spectrum imaging. Neuroimage; 2010 Jan 15;49(2):1231-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For this reason, DTI tractography is not effective for delineating the structural changes that occur in the developing brain, where the process of myelination is incomplete, and where crossing fibers exist in greater numbers than in the adult brain.
  • Using DSI tractography, we successfully identified structural changes in thalamo-cortical and cortico-cortical association tracts in cat brains from one stage of development to another.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2008 Feb;131(Pt 2):573-82 [18222994.001]
  • [Cites] Neuroimage. 2005 Oct 1;27(4):862-71 [15978841.001]
  • [Cites] Magn Reson Med. 2005 Dec;54(6):1377-86 [16247738.001]
  • [Cites] Eur J Radiol. 2006 Feb;57(2):199-216 [16413984.001]
  • [Cites] J Neurosci. 2008 Feb 6;28(6):1427-33 [18256263.001]
  • [Cites] J Neurosci. 2008 Feb 20;28(8):1943-8 [18287510.001]
  • [Cites] Neuroimage. 2008 May 15;41(1):7-18 [18387822.001]
  • [Cites] Dev Neurosci. 2008;30(4):262-75 [17962716.001]
  • [Cites] J Comput Assist Tomogr. 1991 Mar-Apr;15(2):188-98 [2002094.001]
  • [Cites] Radiology. 1991 Jul;180(1):229-33 [2052700.001]
  • [Cites] J Neurosci. 1992 Jan;12(1):39-55 [1729444.001]
  • [Cites] Vis Neurosci. 1993 Jan-Feb;10(1):117-30 [8424921.001]
  • [Cites] Magn Reson Med. 1994 Apr;31(4):394-400 [8208115.001]
  • [Cites] Annu Rev Neurosci. 1994;17:185-218 [8210173.001]
  • [Cites] Annu Rev Neurosci. 1994;17:419-39 [8210182.001]
  • [Cites] J Magn Reson B. 1994 Mar;103(3):247-54 [8019776.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jan-Feb;19(1):28-33 [7529780.001]
  • [Cites] Eur J Neurosci. 1994 Nov 1;6(11):1729-42 [7874312.001]
  • [Cites] J Comp Neurol. 1995 Dec 11;363(2):161-76 [8642068.001]
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] Acta Anat (Basel). 1997;158(3):215-21 [9394958.001]
  • [Cites] Ann Neurol. 1997 Dec;42(6):951-62 [9403488.001]
  • [Cites] Radiology. 1998 Oct;209(1):57-66 [9769812.001]
  • [Cites] Pediatr Res. 1998 Oct;44(4):584-90 [9773850.001]
  • [Cites] Radiology. 1999 Jan;210(1):133-42 [9885598.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):265-9 [9989633.001]
  • [Cites] Magn Reson Med. 1999 Jul;42(1):37-41 [10398948.001]
  • [Cites] J Neurosci. 1999 Aug 15;19(16):6965-78 [10436053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10422-7 [10468624.001]
  • [Cites] Invest Radiol. 2005 Feb;40(2):110-5 [15654256.001]
  • [Cites] J Neurosci. 2005 Feb 23;25(8):1881-8 [15728827.001]
  • [Cites] Neuroimage. 2006 May 1;30(4):1121-32 [16413790.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):27-38 [16905335.001]
  • [Cites] Semin Fetal Neonatal Med. 2006 Dec;11(6):415-22 [16962836.001]
  • [Cites] Pediatr Radiol. 2006 Nov;36(11):1133-40 [16960686.001]
  • [Cites] Neuroimage. 2007 Jan 15;34(2):827-38 [17123836.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Pediatr Radiol. 2007 Aug;37(8):769-80 [17598098.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1267-77 [18495497.001]
  • [Cites] Cereb Cortex. 2008 Aug;18(8):1771-8 [18165283.001]
  • [Cites] Neuroimage. 2008 Nov 1;43(2):213-24 [18694838.001]
  • [Cites] Cereb Cortex. 2009 Mar;19(3):675-87 [18653668.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4263-73 [19339620.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):771-90 [10963122.001]
  • [Cites] Magn Reson Med. 2000 Oct;44(4):625-32 [11025519.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):534-46 [11276097.001]
  • [Cites] Brain Res Bull. 2001 Feb;54(3):255-66 [11287130.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Sep;22(8):1572-6 [11559509.001]
  • [Cites] Radiology. 2002 Jan;222(1):212-8 [11756728.001]
  • [Cites] Cereb Cortex. 2002 Dec;12(12):1237-43 [12427675.001]
  • [Cites] Neuroimage. 2002 Sep;17(1):77-94 [12482069.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):543-52 [12489100.001]
  • [Cites] Neuroimage. 2003 Jul;19(3):482-95 [12880782.001]
  • [Cites] Neuroimage. 2003 Nov;20(3):1639-48 [14642474.001]
  • [Cites] Radiology. 2003 Dec;229(3):673-81 [14657305.001]
  • [Cites] Magn Reson Imaging. 2003 Dec;21(10):1131-40 [14725920.001]
  • [Cites] Neuroimage. 2004 Jul;22(3):1134-40 [15219585.001]
  • [Cites] Neuroimage. 2004 Jul;22(3):1302-14 [15219602.001]
  • [Cites] Nature. 1979 Jul 19;280(5719):231-4 [450139.001]
  • [Cites] J Neurol Sci. 1982 Apr;54(1):33-45 [7077354.001]
  • [Cites] J Comp Neurol. 1985 Dec 22;242(4):611-31 [4086673.001]
  • [Cites] J Neuropathol Exp Neurol. 1987 May;46(3):283-301 [3559630.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):173-80 [3336675.001]
  • [Cites] J Neurosci. 1990 Apr;10(4):1134-53 [2329372.001]
  • [Cites] Neuroradiology. 1990;31(6):459-70 [2352626.001]
  • [Cites] J Comp Neurol. 1990 Jul 15;297(3):441-70 [2398142.001]
  • [Cites] J Neurocytol. 1990 Dec;19(6):883-98 [2292718.001]
  • [Cites] Hum Brain Mapp. 2008 Jan;29(1):14-27 [17318834.001]
  • (PMID = 19747553.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R56 MH064044; United States / NIMH NIH HHS / MH / R01 MH 64044; United States / NIMH NIH HHS / MH / R01 MH064044; United States / NIMH NIH HHS / MH / R01 MH064044-05; United States / NICHD NIH HHS / HD / P01 HD057853; United States / NIMH NIH HHS / MH / MH064044-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoxazines; 0 / Indoles; 0 / Oxazines; 1328-51-4 / Luxol Fast Blue MBS; 18472-89-4 / cresyl violet
  • [Other-IDs] NLM/ NIHMS144810; NLM/ PMC2789885
  •  go-up   go-down


8. Borawski J, Wilczyńska-Borawska M, Stokowska W, Myśliwiec M: The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients. Nephrol Dial Transplant; 2007 Feb;22(2):457-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients.
  • BACKGROUND: Periodontitis contributes to generalized inflammation and development of systemic diseases, including atherosclerosis and cardiovascular disease.
  • Its extent in maintenance haemodialysis (HD) patients is disputable and not known in continuous ambulatory peritoneal dialysis (CAPD) and pre-dialysis chronic kidney disease (CKD) patients.
  • METHODS: One hundred and six patients (35 on HD, mean age, 56 years; 33 on CAPD, mean age 51 years; and 38 pre-dialysis CKD stage 2-5, mean age 51 years) from north-eastern Poland were enrolled.
  • Dialysis subjects were recruited from a cohort of 141 HD and 61 CAPD patients.
  • RESULTS: Average values of the indices in HD, CAPD, pre-dialysis CKD, advanced periodontitis and general population subjects were as follows: GI-1.37, 0.95, 1, 2 and 1; PBI-1.45, 0, 0, 2.20 and 1; PI-2.05, 1.59, 1, 2 and 1; and CAL loss-5.11, 3.47, 2.50, 4.68 and 1.40 mm, respectively.
  • The disease was most advanced in maintenance HD patients-comparable to the full-symptomatic form of periodontitis; then it was successively diminished in CAPD and pre-dialysis CKD subjects.
  • CONCLUSIONS: Periodontal disease is prevalent, severe and under recognized in renal failure patients.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Poland / epidemiology. Prognosis. Retrospective Studies


9. Lewicky-Gaupp C, Margulies RU, Larson K, Fenner DE, Morgan DM, DeLancey JO: Self-perceived natural history of pelvic organ prolapse described by women presenting for treatment. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Aug;20(8):927-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Self-discovery is associated with higher stage prolapse than prolapse diagnosed by health care providers.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2000 Aug;183(2):277-85 [10942459.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):548.e1-6 [18455530.001]
  • [Cites] Scand J Prim Health Care. 2002 Jun;20(2):102-7 [12184708.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2003 Feb;14(1):46-9; discussion 49 [12601516.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):70-5 [12861141.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):27-32 [14749630.001]
  • [Cites] J Am Geriatr Soc. 1994 Feb;42(2):208-12 [8126338.001]
  • [Cites] Obstet Gynecol. 1997 Apr;89(4):501-6 [9083302.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 May-Jun;16(3):203-9; discussion 209 [15875236.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):53-7 [16021058.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):103-13 [16021067.001]
  • [Cites] Scand J Urol Nephrol. 2005;39(4):301-7 [16118105.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Jul-Aug;16(4):272-84 [15856132.001]
  • [Cites] Am J Obstet Gynecol. 2006 May;194(5):1455-61 [16647928.001]
  • [Cites] Arch Intern Med. 2006 May 22;166(10):1128-33 [16717176.001]
  • [Cites] Obstet Gynecol. 2007 Apr;109(4):848-54 [17400845.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):86.e1-6 [17618770.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 Mar;19(3):437-40 [17896064.001]
  • [Cites] Am J Obstet Gynecol. 2001 Dec;185(6):1332-7; discussion 1337-8 [11744905.001]
  • (PMID = 19390760.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD 38665; United States / NICHD NIH HHS / HD / P50 HD044406; United States / NICHD NIH HHS / HD / HD038665-10; United States / NICHD NIH HHS / HD / P50 HD044406-07; United States / NICHD NIH HHS / HD / R01 HD038665-10; United States / NICHD NIH HHS / HD / 1 P50 HD044406; United States / NICHD NIH HHS / HD / R01 HD038665; United States / NICHD NIH HHS / HD / HD044406-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140396; NLM/ PMC2775043
  •  go-up   go-down


10. Shin SJ, Kim HW, Chung S, Chung HW, Lee SJ, Kim YS, Bang BK, Chang YS, Park CW: Late referral to a nephrologist increases the risk of uremia-related cardiac hypertrophy in patients on hemodialysis. Nephron Clin Pract; 2007;107(4):c139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis and outcome of patients with end-stage renal disease are related to the quality of predialysis care and the timing of referral.
  • Late referral (LR) has been correlated with more frequent hospital admissions, malnutrition and cardiovascular mortality after hemodilaysis (HD) is started.
  • METHODS: We investigated the effects of LR on cardiac hypertrophy, uremia-related metabolic risk factors and mortality in patients on HD.
  • A baseline echocardiography was performed in 119 patients on HD, 67 of whom were early referrals (ER, referred more than 3 months before the start of HD) and 52 were LR (referred less than 3 months before the start of HD; median (range): 22.5 (4-120) vs. 1.0 (0-3) months, respectively).
  • More patients in the LR group died of cardiovascular disease compared to the ER patients (p = 0.04).
  • Interestingly, the duration of the pre-HD treatment, after referral, was positively associated with the plasma albumin (r = 0.229; p = 0.01) and negatively associated with the log CRP (r = -0.350; p < 0.001), iPTH (r = -0.309; p = 0.001) and LVMi (r = -0.268; p = 0.004).
  • Multiple linear regression analysis also demonstrated that the log CRP and iPTH as well as the LR were independently associated with LVMi in the HD patients (p < 0.05).
  • CONCLUSIONS: The results of this study demonstrated that the LR HD patients were at an increased risk for more cardiovascular related mortality, severe concentric LVH and systolic dysfunction accompanied by inflammatory and malnutrition indices, as well as with increased iPTH levels.
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Echocardiography, Doppler. Female. Humans. In Vitro Techniques. Incidence. Linear Models. Male. Middle Aged. Nephrology / standards. Nephrology / trends. Probability. Prognosis. Reference Values. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel
  • (PMID = 17957125.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD: Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res; 2010 Jun 1;161(1):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of surgical excision on survival of patients with stage IV breast cancer.
  • BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial.
  • Our aim was to determine whether surgery improves survival in stage IV patients.
  • METHODS: We reviewed records of all stage IV breast cancer patients (1990-2000) at our institution.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Female. Humans. Kaplan-Meier Estimate. Linear Models. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies. Virginia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19375721.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


12. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS: Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord; 2008 Jun 15;23(8):1100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease.
  • The purpose of this study was to quantify gait impairments in presymptomatic and symptomatic Huntington's disease (HD) subjects, and examine sensitivity of gait measures.
  • Our sample (n = 65) included presymptomatic mutation carriers (PMC) (n = 15), symptomatic HD subjects (SHD) (n = 30) and healthy controls (n = 20).
  • We administered the Unified HD Rating Scale (UHDRS) for PMC and SHD.
  • These impairments worsened with increasing disease severity for SHD.
  • Gait bradykinesia and dynamic balance impairments begin in the presymptomatic stage of HD and continue to worsen in the symptomatic stages.
  • [MeSH-major] Gait Disorders, Neurologic / diagnosis. Huntington Disease / diagnosis
  • [MeSH-minor] Adult. DNA Mutational Analysis. Early Diagnosis. Female. Heterozygote Detection. Humans. Male. Middle Aged. Nerve Tissue Proteins / genetics. Neurologic Examination. Nuclear Proteins / genetics. Postural Balance. Predictive Value of Tests. Signal Processing, Computer-Assisted. Software. Trinucleotide Repeats / genetics

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • MedlinePlus Health Information. consumer health - Walking Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412252.001).
  • [ISSN] 1531-8257
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


13. Chatterjee A, Bosch RJ, Kupka R, Hunter DJ, Msamanga GI, Fawzi WW: Predictors and consequences of anaemia among antiretroviral-naïve HIV-infected and HIV-uninfected children in Tanzania. Public Health Nutr; 2010 Feb;13(2):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Advanced maternal clinical HIV disease (relative risk (RR) for stage > or =2 v. stage 1: 1.31, 95 % CI 1.14, 1.51) and low CD4 cell counts during pregnancy (RR for <350 cells/mm3 v. > or =350 cells/mm3: 1.58, 95 % CI 1.05, 2.37) were associated with increased risk of anaemia among children.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1989 Jun 22;320(25):1643-8 [2657430.001]
  • [Cites] AIDS. 2008 Jan 2;22(1):97-105 [18090397.001]
  • [Cites] J Nutr. 2001 Feb;131(2S-2):568S-579S; discussion 580S [11160590.001]
  • [Cites] Am J Trop Med Hyg. 2000 May;62(5):590-7 [11289670.001]
  • [Cites] J Investig Med. 2001 May;49(3):225-39 [11352180.001]
  • [Cites] J Nutr. 2002 Mar;132(3):423-9 [11880566.001]
  • [Cites] Ann Trop Paediatr. 2002 Mar;22(1):11-7 [11926044.001]
  • [Cites] Pediatrics. 2002 Aug;110(2 Pt 1):e25 [12165624.001]
  • [Cites] BMC Infect Dis. 2002;2:3 [11866864.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1347-60 [12423980.001]
  • [Cites] AIDS. 2003 Apr 11;17(6):867-77 [12660534.001]
  • [Cites] Am J Med. 2004 Apr 5;116 Suppl 7A:27S-43S [15050884.001]
  • [Cites] J Clin Pathol. 1970 Feb;23(1):68-76 [5439092.001]
  • [Cites] Arch Dis Child. 1973 Nov;48(11):864-6 [4761054.001]
  • [Cites] Br Med J. 1975 Aug 30;3(5982):522 [1080682.001]
  • [Cites] Acta Paediatr Scand. 1985 Sep;74(5):701-6 [4050416.001]
  • [Cites] World Health Stat Q. 1985;38(3):302-16 [3878044.001]
  • [Cites] Pediatrics. 1987 Jun;79(6):981-95 [2438638.001]
  • [Cites] AIDS. 1990 Dec;4(12):1231-6 [2088400.001]
  • [Cites] Pediatr Res. 1992 Aug;32(2):155-9 [1508604.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):308-12 [7904046.001]
  • [Cites] Am J Trop Med Hyg. 1994 Aug;51(2):170-4 [8074250.001]
  • [Cites] Cent Afr J Med. 1994 Dec;40(12):333-6 [7882412.001]
  • [Cites] J Pediatr. 1997 Jun;130(6):890-7 [9202610.001]
  • [Cites] Am J Trop Med Hyg. 1998 May;58(5):606-11 [9598449.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1477-82 [9605804.001]
  • [Cites] Gynecol Obstet Invest. 1999;47(2):76-82 [9949275.001]
  • [Cites] AIDS. 1999 May 28;13(8):943-50 [10371175.001]
  • [Cites] Arch Dis Child. 1951 Jun;26(127):205-14 [14857788.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):219-25 [16186741.001]
  • [Cites] Lancet. 2006 Jan 14;367(9505):133-43 [16413877.001]
  • [Cites] Lancet. 2006 Jan 14;367(9505):144-52 [16413878.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):599-606 [18043314.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Winter;12(4):449-53 [2285125.001]
  • (PMID = 19650963.001).
  • [ISSN] 1475-2727
  • [Journal-full-title] Public health nutrition
  • [ISO-abbreviation] Public Health Nutr
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000004; United States / NIDDK NIH HHS / DK / P30 DK040561; United States / NIDDK NIH HHS / DK / P30 DK040561-14; United States / NICHD NIH HHS / HD / R01 HD032257
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antimalarials
  • [Other-IDs] NLM/ NIHMS338499; NLM/ PMC3775572
  •  go-up   go-down


14. Pistorius S, Kruger S, Hohl R, Plaschke J, Distler W, Saeger HD, Schackert HK: Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. Gynecol Oncol; 2006 Aug;102(2):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylactic hysterectomy with oophorectomy was considered in postmenopausal women meeting the Amsterdam criteria and/or carrying a disease causing mismatch repair gene mutation who were operated on because of diagnosed colorectal cancer in our center for hereditary cancer.
  • Postoperative histological examination showed EC stage T1b N0 M0 in 2 patients.
  • [MeSH-minor] Adult. Female. Genetic Counseling. Genetic Predisposition to Disease. Humans. Hysterectomy. Middle Aged. Retrospective Studies


15. Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, Skepper JN, Wight JM: Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis; 2009 Mar;33(3):331-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
  • Huntington's disease (HD) is caused by an expanded CAG repeat in the HD gene.
  • The pathological threshold for expansion in HD is around 36 CAG repeats, although 'super-long' expansions are found in brains of HD patients.
  • Unexpectedly, we found that increasing the repeat length delayed onset of disease and prolonged survival, from around 4 months to over 18 months in mice with the longest repeats.
  • Furthermore, neurodegeneration is present in super-long repeat length mice at mid-stage disease, whereas little neurodegeneration is seen in mice with shorter CAG repeats until end stage.
  • Expanding the CAG repeat beyond the range where NII formation is the dominant pathology has unmasked a slowly progressing neurological phenotype in R6/2 mice with brain pathology, including the identification of a novel form of inclusion, that more closely resembles that seen in adult onset cases of HD.
  • This mouse may represent a better model for adult-onset HD than R6/2 mice with shorter repeats.
  • [MeSH-major] Huntington Disease / genetics. Nerve Tissue Proteins / genetics. Nuclear Proteins / genetics. Trinucleotide Repeat Expansion
  • [MeSH-minor] Age of Onset. Aging. Animals. Body Weight. Brain / pathology. Brain / ultrastructure. Disease Progression. Humans. Intranuclear Inclusion Bodies / ultrastructure. Mice. Mice, Transgenic. Motor Activity. Nerve Degeneration. Neurons / physiology. Neurons / ultrastructure. Phenotype. Postural Balance. Survival Rate

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130884.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


16. Wu BB, Zhang LM, Mei CL, Tang Q, Lu YZ: [Relationship between serum free fatty acid and cytokines, carotid atherosclerosis in chronic kidney disease]. Zhonghua Nei Ke Za Zhi; 2010 Jul;49(7):572-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum free fatty acid and cytokines, carotid atherosclerosis in chronic kidney disease].
  • OBJECTIVE: To investigate the serum level of free fatty acid (FFA) and explore its relationship with cytokines and atherosclerosis (AS) in chronic kidney disease (CKD).
  • We evaluated the relationship between serum levels of FFA and IL-1β, IL-6, TNFα, hsCRP as well as the renal function in 130 adult patients with CKD, stratified according to the GFR (based on the National Kidney Foundation/Kidney Dialysis Outcomes Quality Initiatives) and in 58 hemodialytic (HD) patients.
  • RESULTS: The serum level of FFA was significantly higher in CKD patients as compared with that in the healthy controls [(492.63±143.59) vs (302.65±142.18) µmol/L, P<0.01], even in the early stage of CKD.
  • In the non-dialytic CKD group, the level of FFA was negatively related to GFR and positively related to the proteinuria (P<0.05), while in the HD group, it was positively correlated with dialysis duration (P<0.05).
  • CONCLUSION: Serum levels of FFA are significantly higher either in non-dialytic CKD or in HD patients and it is related with hsCRP, IL-1β, IL-6, TNFα as well as carotid artery atherosclerosis, indicating that FFA is an independent risk factor of AS in CKD.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged


17. Locatelli F, Dimkovic N, Pontoriero G, Spasovski G, Pljesa S, Kostic S, Manning A, Sano H, Nakajima S: Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant; 2010 Feb;25(2):574-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyperphosphataemia in patients on haemodialysis (HD) can lead to, or worsen, secondary hyperparathyroidism (with associated bone disease) and extra-skeletal calcifications associated with increased cardiovascular morbidity and mortality.
  • The aim of this study was to determine the effect of three fixed doses of MCI-196, on serum phosphorus level and other parameters relevant to HD patients.
  • METHODS: A total of 120 chronic kidney disease (CKD) stage 5 patients on HD and with the serum phosphorus level >2.1 mmol/l were randomized to receive double-blind treatment with either 3, 6 and 9 g/day MCI-196 or placebo for 3 weeks.
  • The additional reduction in total cholesterol and LDL cholesterol indicates a possible dual mechanism of action of MCI-196 that has the potential to reduce cardiovascular morbidity in CKD stage 5 patients.
  • [MeSH-minor] Adult. Aged. Double-Blind Method. Female. Humans. Kidney Diseases / blood. Kidney Diseases / therapy. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736246.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / cholebine; 27YLU75U4W / Phosphorus; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


18. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer; 2006 Jul 1;107(1):90-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: EMP2 immunophenotype, histologic diagnosis, grade, the presence of lymphovascular invasion, disease stage, and clinical follow-up were determined for 99 endometrial cancers.
  • EMP2-positive tumors were more likely than others to be myometrium invasive, high stage, and recurrent, persistent, or fatal.
  • The median disease-free interval was only 11 months for patients with EMP2-positive tumors and was not reached for patients with EMP2-weak and EMP2-negative tumors.
  • A multivariate analysis of disease-free survival demonstrated independent, negative prognostic significance for EMP2 expression, high stage, and high-risk histologic subtypes.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16736513.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16042-29; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / HD048540; United States / NCATS NIH HHS / TR / UL1 TR000124; United States / NICHD NIH HHS / HD / HD40376; United States / NCI NIH HHS / CA / T32 CA009120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EMP2 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


19. Zhang AH, Cheng LT, Zhu N, Sun LH, Wang T: Comparison of quality of life and causes of hospitalization between hemodialysis and peritoneal dialysis patients in China. Health Qual Life Outcomes; 2007;5:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemodialysis (HD) and peritoneal dialysis (PD) are important renal replacement treatment in end stage renal disease (ESRD), but the comparison of quality of life (QOL) and causes of hospitalisation between the two modalities in China is lacking.
  • SUBJECTS AND METHODS: Six hundred and fifty four HD and 408 PD patients were investigated from 10 hospitals in China from Sept, 2004 to Jan, 2005.
  • Among the HD patients, there were 360 males and 294 females with a mean age of 57.22 +/- 12.49 years (18-88 y).
  • RESULTS: SF-36 domains of Body Pain (BP), General Health (GH), Role-Emotional (RE), Social Functioning (SF), Vitality (VT) and Mental Health (MH) were all significantly higher in the PD patients as compared to the HD patients although there was no significant difference in Physical Functioning (PF) and Role-Physical (RP) between the two groups.
  • The two most common causes of hospitalisation in HD patients were cardiovascular disease (39.8%) and pulmonary infection (21.3%), while they were infectious peritonitis (47.6%) and cardiovascular disease (31.9%) in PD patients.
  • CONCLUSION: Our study indicated that with the current practice in China, PD patients may enjoy better quality of life than their HD counterparts.
  • Our results also showed that the most common cause of hospitalisation was cardiovascular disease in HD patients and peritonitis in PD patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. China. Female. Hospitalization. Humans. Male. Middle Aged. Process Assessment (Health Care). Psychometrics. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Purif. 2005;23(4):330-7 [16118488.001]
  • [Cites] Health Qual Life Outcomes. 2005;3:74 [16305743.001]
  • [Cites] Am J Kidney Dis. 2000 Feb;35(2):293-300 [10676729.001]
  • [Cites] Am J Kidney Dis. 2001 Feb;37(2):337-42 [11157375.001]
  • [Cites] J Am Soc Nephrol. 2001 Dec;12(12):2797-806 [11729250.001]
  • [Cites] Perit Dial Int. 2001;21 Suppl 3:S378-83 [11887861.001]
  • [Cites] Kidney Int. 2002 Nov;62(5):1791-8 [12371981.001]
  • [Cites] Am J Kidney Dis. 2002 Dec;40(6):1185-94 [12460037.001]
  • [Cites] Nephrol Dial Transplant. 2005 Jun;20(6):1180-6 [15769823.001]
  • [Cites] Perit Dial Int. 1998 Jul-Aug;18(4):387-94 [10505560.001]
  • [Cites] Kidney Int. 1999 Aug;56(2):720-8 [10432414.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1503-10 [10383015.001]
  • [Cites] Am J Kidney Dis. 1997 Aug;30(2):204-12 [9261030.001]
  • [Cites] Am J Kidney Dis. 1994 Aug;24(2):267-79 [8048434.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Nephrol Dial Transplant. 2004 Jun;19(6):1594-9 [15004254.001]
  • [Cites] Clin Nephrol. 2003 Nov;60(5):341-51 [14640240.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):743-53 [14978177.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 18;43(4):583-4 [14975467.001]
  • [Cites] Nephrol Dial Transplant. 2004 Feb;19(2):413-20 [14736967.001]
  • [Cites] Nephrol Dial Transplant. 2004 Jan;19(1):108-20 [14671046.001]
  • [Cites] Kidney Int. 2004 Jun;65(6):2380-9 [15149351.001]
  • (PMID = 17678543.001).
  • [ISSN] 1477-7525
  • [Journal-full-title] Health and quality of life outcomes
  • [ISO-abbreviation] Health Qual Life Outcomes
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1988788
  •  go-up   go-down


20. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, Borum P, Meyer WA 3rd, Hardin DS, Mulligan K, Pediatric AIDS Clinical Trials Group P1045 team: Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS; 2009 Mar 27;23(6):661-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Cross-sectional multicenter study on HIV-infected (HIV-positive) patients, 7-24 years of age, stratified by Tanner stage and protease inhibitor use (protease inhibitor, n = 161 and non- protease inhibitor, n = 79) and seronegative controls (HIV-negative, n = 146).
  • Protease inhibitor and nonprotease inhibitor groups had similar current CD4 cell count and HIV-1 RNA, but the protease inhibitor group had lower nadir CD4 cell count, higher peak HIV-1 RNA, and more advanced Centers for Disease Control disease stage.
  • There was a high prevalence of lipid abnormalities among those on protease inhibitors and evidence of developing insulin resistance, factors that may accelerate lifetime risk for cardiovascular disease.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] MMWR Morb Mortal Wkly Rep. 2008 Aug 1;57(30):817-22 [18668019.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):802-10 [11893791.001]
  • [Cites] Arch Dis Child. 2002 Jun;86(6):407-10 [12023168.001]
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):290-2; author reply 290-2 [12141328.001]
  • [Cites] Pediatr Infect Dis J. 2002 May;21(5):405-10 [12150177.001]
  • [Cites] Lancet. 2002 Aug 10;360(9331):473-82 [12241736.001]
  • [Cites] JAMA. 2002 Oct 2;288(13):1622-31 [12350193.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75 [12439201.001]
  • [Cites] Pediatr Infect Dis J. 2003 Jan;22(1):77-84 [12544413.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1435-41 [12824780.001]
  • [Cites] BMJ. 2003 Nov 1;327(7422):1019 [14593035.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):24-8 [14715822.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1605-12 [15156450.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2362-74 [15175438.001]
  • [Cites] AIDS. 2004 Jul 2;18(10):1443-51 [15199321.001]
  • [Cites] Pediatrics. 2004 Aug;114(2):e235-42 [15286262.001]
  • [Cites] J Infect Dis. 2004 Sep 1;190(5):908-12 [15295695.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] N Engl J Med. 1986 Jul 24;315(4):215-9 [3523245.001]
  • [Cites] Am J Epidemiol. 1991 Apr 1;133(7):704-14 [2018025.001]
  • [Cites] Pediatrics. 1992 Mar;89(3):495-501 [1741227.001]
  • [Cites] Am J Health Promot. 1992 Jul-Aug;6(6):430-6 [10148719.001]
  • [Cites] Am J Epidemiol. 1995 Mar 1;141(5):428-39 [7879787.001]
  • [Cites] J Nutr. 1996 Oct;126(10 Suppl):2641S-2650S [8861928.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Arch Pediatr Adolesc Med. 1998 Jul;152(7):688-93 [9667542.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1243-4 [10217092.001]
  • [Cites] Circulation. 1999 Aug 17;100(7):700-5 [10449690.001]
  • [Cites] J Pediatr. 2004 Dec;145(6):731-6 [15580192.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):18-22 [15608519.001]
  • [Cites] N Engl J Med. 2005 Jan 6;352(1):48-62 [15635112.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):168-74 [15483082.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7 [15764965.001]
  • [Cites] Eur J Pediatr. 2005 May;164(5):271-6 [15650834.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):659-76, ix-x [16085165.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):121-31 [16186728.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):161-8 [16186733.001]
  • [Cites] Acta Paediatr. 2005 Jun;94(6):672-7 [16188767.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):453-60 [16652053.001]
  • [Cites] Diabetes Care. 2006 Jun;29(6):1433-8 [16732040.001]
  • [Cites] Clin Infect Dis. 2006 Sep 1;43(5):645-53 [16886161.001]
  • [Cites] Clin Infect Dis. 2006 Sep 1;43(5):658-60 [16886163.001]
  • [Cites] Curr Diab Rep. 2006 Jun;6(3):241-50 [16898579.001]
  • [Cites] Endocr Pract. 2006 Sep-Oct;12(5):514-21 [17014060.001]
  • [Cites] Eur J Pediatr. 2007 Jan;166(1):13-21 [16896646.001]
  • [Cites] Atherosclerosis. 2007 Mar;191(1):98-106 [17054960.001]
  • [Cites] Circulation. 2007 Apr 10;115(14):1948-67 [17377073.001]
  • [Cites] Metabolism. 2007 May;56(5):614-22 [17445535.001]
  • [Cites] AIDS. 2007 May 11;21(8):921-7 [17457085.001]
  • [Cites] Antivir Ther. 2007;12(3):297-302 [17591019.001]
  • [Cites] Eur J Endocrinol. 2007 Nov;157(5):655-9 [17984246.001]
  • [Cites] AIDS. 2000 Jan 7;14(1):51-7 [10714567.001]
  • [Cites] Diabetes Care. 2000 Mar;23(3):381-9 [10868870.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):190-7 [10889592.001]
  • [Cites] Adv Data. 2000 Jun 8;(314):1-27 [11183293.001]
  • [Cites] Pharmacotherapy. 2001 Jul;21(7):861-6 [11444583.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1117-23 [11522181.001]
  • [Cites] Diabetes. 2001 Nov;50(11):2444-50 [11679420.001]
  • [Cites] N Engl J Med. 2001 Nov 22;345(21):1522-8 [11794218.001]
  • [Cites] AIDS. 2001 Dec 7;15(18):2415-22 [11740192.001]
  • [Cites] Pediatr Diabetes. 2007 Dec;8 Suppl 9:7-15 [17991128.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2183-90 [18090045.001]
  • [Cites] Diabetes Care. 2008 Jun;31(6):1224-9 [18268071.001]
  • [Cites] Pediatrics. 2008 Jul;122(1):198-208 [18596007.001]
  • [Cites] J Pediatr. 2008 Aug;153(2):209-14 [18534231.001]
  • (PMID = 19279441.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD040777-07; United States / NCRR NIH HHS / RR / M01 RR000069; United States / NIAID NIH HHS / AI / U01 AI068632; United States / NCRR NIH HHS / RR / RR-001271; United States / NIAID NIH HHS / AI / U01 AI068632-03; United States / NICHD NIH HHS / HD / R01 HD040777-07; United States / NIAID NIH HHS / AI / U01 AI41089; United States / NIAID NIH HHS / AI / U01 AI041089-09; United States / NICHD NIH HHS / HD / R01 HD040777; United States / NCRR NIH HHS / RR / M01 RR001271; United States / NIAID NIH HHS / AI / U01 AI041110-09; United States / NIAID NIH HHS / AI / U01 AI041110; United States / NCRR NIH HHS / RR / M01 RR00069; United States / NIAID NIH HHS / AI / U01 AI041089; United States / NICHD NIH HHS / HD / R01 HD 40777; United States / NIAID NIH HHS / AI / 5 U01 AI41110; United States / NIAID NIH HHS / AI / AI041089-09; United States / NIAID NIH HHS / AI / UM1 AI106716
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Blood Glucose; 0 / HIV Protease Inhibitors; 0 / Lipids
  • [Other-IDs] NLM/ NIHMS89961; NLM/ PMC2680185
  • [Investigator] Yogev R; Talsky A; Williams R; Cagwin E; Silio M; Alchediak T; Borne C; Bradford S; Nachman S; Ferraro D; Perillo J; Muniz S; Donohoe M; Patel N; Kaste S; Utech J; Barr E; Maes J; McFarland B; Paul S; Hurwitz J; Simonetti J; Donnelly M; Mathison C; Andiman W; Hurst L; Romano S; Weinberg G; Murante B; Laverty S; Dobbins D; Peron T; Wimbley D; Spiegel H; Pass R; Crain M; Beatty N
  •  go-up   go-down


21. Leinig C, Pecoits-Filho R, Nascimento MM, Gonçalves S, Riella MC, Martins C: Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients. J Ren Nutr; 2008 Sep;18(5):424-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
  • OBJECTIVE: Chronic kidney disease (CKD) patients may present with altered body composition.
  • Chronic kidney disease patients were divided, according to K/DOQI guidelines, into 27 subjects at stages 3 to 4 (mean glomerular filtration rate of 43 +/- 12 mL/minute; age, 52 +/- 10 years), and 51 at stage 5: 25 in hemodialysis (HD) (aged 45, SD +/- 12 years; 44% male), and 26 in peritoneal dialysis (PD) (aged 49, SD +/- 13 years; 42% male).
  • RESULTS: There was no difference in median BMI (kg/m(2)) among healthy control subjects (24.8; range, 19.2-34.1), CKD stages 3 to 4 (26.4; range, 20.4-37.6), HD patients (24.5; range, 19.4-35.7), and PD patients (24.5; range, 20.2-37.7; P > .05).
  • Likewise, no significant difference was verified in median body FM (kg) among control subjects (18.8; range, 9.2-36.5), CKD stages 3 to 4 (21.2; range, 11.6-37.9), HD patients (17.1; range, 4.8-38.9), and PD patients (20.1; range, 6.5-41.5; P > .05).
  • Moreover, a positive and significant correlation was found between BMI and FM (kg) in CKD stages 3 to 4 (Rho = 0.67, P = .0002), in HD patients (Rho = 0.67, P = .0002), in PD patients (Rho = 0.79, P < .0001), and in control subjects (Rho = 0.79, P < .0001).
  • Although BMI and lean body mass (in kg) was significantly correlated in CKD stages 3 to 4 (Rho = 0.58, P = .001) and healthy control subjects (Rho = 0.30, P = .007), no significant correlation was found in HD patients (Rho = 0.19, P = .34) and in PD patients (Rho = 0.17, P = .38).
  • [MeSH-minor] Absorptiometry, Photon / methods. Adolescent. Adult. Aged. Biomarkers. Case-Control Studies. Female. Humans. Male. Middle Aged. Severity of Illness Index. Young Adult

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721737.001).
  • [ISSN] 1532-8503
  • [Journal-full-title] Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation
  • [ISO-abbreviation] J Ren Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


22. Afsar B, Ozdemir NF, Sezer S, Haberal M: Quality of life is not related with liver disease severity but with anemia, malnutrition, and depression in HCV-infected hemodialysis patients. Hemodial Int; 2009 Jan;13(1):62-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life is not related with liver disease severity but with anemia, malnutrition, and depression in HCV-infected hemodialysis patients.
  • The relationship between HCV infection and quality of life in hemodialysis (HD) patients is unknown.
  • Patients with a high stage of liver fibrosis had lower social functioning scores than patient with a low stage of fibrosis (P= 0.011).
  • Quality of life in HCV-infected HD patients was independent of liver disease severity anchors, but was correlated with anemia, malnutrition, and depression.
  • [MeSH-minor] Adult. Female. Health Status. Humans. Liver / enzymology. Liver / pathology. Liver / virology. Male. Middle Aged. Serum Albumin / analysis. Viral Load


23. Ali ME, Abdel-Hafez HZ, Mahran AM, Mohamed HZ, Mohamed ER, El-Shazly AM, Gadallah AM, Abbas MA: Erectile dysfunction in chronic renal failure patients undergoing hemodialysis in Egypt. Int J Impot Res; 2005 Mar-Apr;17(2):180-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In clinical practice, the attention given to sexual problems in patients with end-stage renal disease is low.
  • In order to evaluate the erectile function in chronic renal failure patients undergoing hemodialysis (HD) as a renal replacement therapy in upper Egypt, we used the abridged version of the International Index of Erectile Function (IIEF-5).
  • In all, 75 HD patients were subjected to clinical and laboratory investigations.
  • The prevalence of erectile dysfunction (ED) among the HD patients was 82.5% compared to 30% among controls.
  • The prevalence of ED in HD group was significantly higher than in controls.
  • The prevalence of ED in HD patients <50 y was 80% and it was 88% in those > or =50 y, while the prevalence of ED among controls was 28 and 69.8%, respectively.
  • The prevalence of severe degree of ED was significantly higher in both groups compared to controls, while moderate degree of ED showed a statistical significance compared to controls in age groups <50 y and mild degree of ED showed a statistical significance compared to controls in age groups > or =50 y. [corrected] Age (r=-0.3368, P<0.01), serum urea (r=-0.5974, P<0.001), and creatinine level (r=-0.5804, P<0.001) have a significant negative correlation with the presence of ED among HD patients, while serum hemoglobin (r=0.3396, P<0.001) and years of HD age (r=0.3147, P<0.01) have a significant positive correlation with the presence of ED among the HD patients.
  • In view of the observed high prevalence of ED among the HD patients, we believe that a complete health evaluation of male HD patients should include a discussion about erectile function in the standard clinical care program of patients with renal disease.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Creatinine / blood. Egypt / epidemiology. Humans. Male. Middle Aged. Prevalence. Risk Factors. Severity of Illness Index. Time Factors. Urea / blood

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Impot Res. 2005 Jul-Aug;17(4):390
  • (PMID = 15549139.001).
  • [ISSN] 0955-9930
  • [Journal-full-title] International journal of impotence research
  • [ISO-abbreviation] Int. J. Impot. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8W8T17847W / Urea; AYI8EX34EU / Creatinine
  •  go-up   go-down


24. Remien RH, Higgins JA, Correale J, Bauermeister J, Dubrow R, Bradley M, Steward WT, Seal DW, Sikkema KJ, Kerndt PR, Mayer KH, Truong HM, Casey CY, Ehrhardt AA, Morin SF: Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. AIDS Behav; 2009 Dec;13(6):1046-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over time and after the acute stage of infection, many participants acquired understanding of AHI from varied sources, including the Internet, HIV-infected friends, and health clinic employees.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4 [16988643.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):213-21 [17146375.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1037-45 [19495954.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1054-60 [19504178.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1068-74 [19504179.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):446-53 [16010168.001]
  • [Cites] Am J Public Health. 2001 Mar;91(3):400-5 [11236404.001]
  • [Cites] Am J Prev Med. 2001 Aug;21(2):84-92 [11457627.001]
  • [Cites] AIDS. 2004 May 21;18(8):1179-86 [15166533.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1057-66 [15247559.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1873-83 [15872202.001]
  • [Cites] AIDS Behav. 2009 Dec;13(6):1061-7 [19517225.001]
  • (PMID = 19533323.001).
  • [ISSN] 1573-3254
  • [Journal-full-title] AIDS and behavior
  • [ISO-abbreviation] AIDS Behav
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH062246; United States / NIMH NIH HHS / MH / L30 MH084308; United States / NIAID NIH HHS / AI / P30AI42853; United States / NIMH NIH HHS / MH / P30 MH062294; United States / NIMH NIH HHS / MH / P30 MH052776; United States / NIMH NIH HHS / MH / P30 MH043520; United States / NIMH NIH HHS / MH / P30MH052776; United States / NIMH NIH HHS / MH / P30MH058107; United States / NICHD NIH HHS / HD / R24 HD047879; United States / NIMH NIH HHS / MH / P30 MH043520-21; United States / NIMH NIH HHS / MH / P30MH062512; United States / NIMH NIH HHS / MH / P30 MH058107; United States / NIAID NIH HHS / AI / U01 AI043638; United States / NIMH NIH HHS / MH / P30MH062294; United States / NIMH NIH HHS / MH / MH084308-01; United States / NIMH NIH HHS / MH / P30 MH062512; United States / NIMH NIH HHS / MH / MH043520-21; United States / NIAID NIH HHS / AI / P30 AI042853; United States / NIMH NIH HHS / MH / L30 MH084308-01; United States / NIAID NIH HHS / AI / AI43638; United States / NIMH NIH HHS / MH / P30MH043520; United States / NIMH NIH HHS / MH / P30MH062246
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS128605; NLM/ PMC2787764
  •  go-up   go-down


25. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • Factors predicting OS were response to conventional salvage therapy and stage prior to salvage therapy.
  • Three prognostic subgroups were defined according to the score determined by stage prior to initiation of salvage chemotherapy, remission duration prior to salvage (refractory/early relapse vs. late relapse) and response to salvage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


26. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS: Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer; 2006 Nov 1;107(9):2212-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The core study was a 2-stage, community-based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti-HCV (n = 4616 individuals) and in townships with a low prevalence of anti-HCV (n = 1694 individuals).
  • RESULTS: Among the individuals who were positive for anti-HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 x 10(3)/mm(3) for a diagnosis of cirrhosis.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Blood Platelets / pathology. Community Health Services. Comorbidity. Female. Hepatitis B / diagnosis. Hepatitis B / epidemiology. Hepatitis C / diagnosis. Hepatitis C / epidemiology. Humans. Liver Cirrhosis / diagnosis. Liver Cirrhosis / epidemiology. Male. Mass Screening. Middle Aged. Pilot Projects. Predictive Value of Tests. Prevalence. Risk Factors. Sensitivity and Specificity. Survival Rate. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019738.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Leonard MB, Elmi A, Mostoufi-Moab S, Shults J, Burnham JM, Thayu M, Kibe L, Wetzsteon RJ, Zemel BS: Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults. J Clin Endocrinol Metab; 2010 Apr;95(4):1681-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regression models were adjusted for tibia length, age, race, sex, and Tanner stage.
  • RESULTS: All cortical measures were greater in blacks than whites (all P < or = 0.001) in Tanner stages 1-4; however, differences in BMC, Peri, and Zp were negligible in Tanner stage 5 (all interactions, P < 0.01).
  • Cortical BMC, Peri, and Zp were lower in females than males in all Tanner stages (all P < 0.001), and the sex differences in Peri and Zp were greater in Tanner stage 5 (interaction, P < 0.02).

  • MedlinePlus Health Information. consumer health - Puberty.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1698-703 [15070933.001]
  • [Cites] Epidemiology. 1994 Jan;5(1):42-7 [8117781.001]
  • [Cites] Osteoporos Int. 1994 Nov;4(6):382-98 [7696836.001]
  • [Cites] Int J Obes Relat Metab Disord. 1995 Sep;19(9):644-52 [8574275.001]
  • [Cites] Bone. 1998 Jan;22(1):1-6 [9437507.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1420-7 [9589632.001]
  • [Cites] Osteoporos Int. 1998;8(5):468-89 [9850356.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):277-82 [16249282.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2087-99 [17311856.001]
  • [Cites] Osteoporos Int. 2007 Jul;18(7):991-7 [17268944.001]
  • [Cites] Bone. 2008 May;42(5):982-9 [18337201.001]
  • [Cites] Rheumatology (Oxford). 2008 Jul;47 Suppl 4:iv2-8 [18556646.001]
  • [Cites] Bone. 2009 May;44(5):970-5 [19442622.001]
  • [Cites] J Bone Miner Res. 2009 Jun;24(6):1075-85 [19113912.001]
  • [Cites] Osteoporos Int. 2009 Jul;20(7):1141-9 [19048179.001]
  • [Cites] Bone. 2009 Aug;45(2):218-25 [19394455.001]
  • [Cites] J Bone Miner Res. 2009 Oct;24(10):1693-8 [19419294.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1095-8 [10720045.001]
  • [Cites] Pediatr Res. 2001 Sep;50(3):309-14 [11518815.001]
  • [Cites] Pediatrics. 2002 Jan;109(1):45-60 [11773541.001]
  • [Cites] Lancet. 2002 May 25;359(9320):1841-50 [12044392.001]
  • [Cites] J Bone Miner Res. 2002 Jun;17(6):1095-101 [12054165.001]
  • [Cites] Bone. 2002 Jul;31(1):110-3 [12110422.001]
  • [Cites] Pediatrics. 2002 Oct;110(4):752-7 [12359790.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1728-32 [12365956.001]
  • [Cites] J Bone Miner Res. 2003 Oct;18(10):1766-74 [14584886.001]
  • [Cites] Bone. 2003 Nov;33(5):771-8 [14623052.001]
  • [Cites] J Clin Densitom. 2009 Jul-Sep;12(3):330-6 [19577939.001]
  • (PMID = 20157194.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK064966; United States / NIDDK NIH HHS / DK / R01-DK60030; United States / NICHD NIH HHS / HD / R01 HD040714; United States / NIDDK NIH HHS / DK / R01 DK060030; United States / NICHD NIH HHS / HD / R01-HD040714; United States / NIDDK NIH HHS / DK / K24-DK076808; United States / NCRR NIH HHS / RR / UL1-RR024134; United States / NIDDK NIH HHS / DK / T32 DK060455; United States / NIDDK NIH HHS / DK / K24 DK076808; United States / NCRR NIH HHS / RR / UL1 RR024134; United States / NIDDK NIH HHS / DK / R01-DK064966
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2853999
  •  go-up   go-down


28. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS: Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):508-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statistical analysis showed that there was a significant difference of CENP-H expression in patients categorized according to clinical stage (P = 0.024) and T classification (P = 0.027).
  • [MeSH-minor] Adult. China. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255272.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CENPH protein, human; 0 / Chromosomal Proteins, Non-Histone
  •  go-up   go-down


29. Kuroki Y, Tsuchida K, Go I, Aoyama M, Naganuma T, Takemoto Y, Nakatani T: A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients. Int J Mol Med; 2007 May;19(5):783-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients.
  • However, no study has been conducted on TLR expression in hemodialysis (HD) patients.
  • The present study was undertaken to examine innate immunity and the roles played by endotoxins (ET) contained in dialysate in HD patients, by analysis of TLR expression and reactivity.
  • TLR-2 and TLR-4 expression on monocytes was investigated by flow cytometry in the following groups of subjects: healthy controls, patients on HD, patients with end-stage renal disease (ESRD) and patients on peritoneal dialysis (PD).
  • Expression of TLR-4 was lower in the HD group than in the healthy controls (p<0.05), while expression of TLR-2 was lower in the PD group than in the healthy controls (p<0.05).
  • Suppression of expression of TLR-4 was noted in HD patients, and TLR-4 expression was reduced as the duration of dialysis became longer.
  • Reduced TLR-4 expression may be associated with the compromised immune function in HD patients.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lipopolysaccharides / pharmacology. Male. Membranes, Artificial. Middle Aged. Peritoneal Dialysis. Time Factors

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390084.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Membranes, Artificial; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4
  •  go-up   go-down


30. Abdelrahman M, Sinha AK, Karkar A: Tuberculosis in end-stage renal disease patients on hemodialysis. Hemodial Int; 2006 Oct;10(4):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis in end-stage renal disease patients on hemodialysis.
  • We aimed in this study to assess and evaluate the presentation of MBT in a retrospective study conducted among 256 hemodialysis (HD) patients where 18 of them were diagnosed and managed for tuberculosis over a 10-year period between 1990 and 2000.
  • The mean interval between the onset of HD and the time of diagnosis was about 24 months (1-120 months).
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunocompromised Host. Male. Middle Aged. Retrospective Studies. Risk Factors. Saudi Arabia


31. Richter HE, Goode PS, Kenton K, Brown MB, Burgio KL, Kreder K, Moalli P, Wright EJ, Weber AM, Pelvic Floor Disorders Network: The effect of age on short-term outcomes after abdominal surgery for pelvic organ prolapse. J Am Geriatr Soc; 2007 Jun;55(6):857-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Controlling for prolapse stage and whether Burch was performed, there were no age differences in complication rates.
  • At 3 and 12 months, there were no differences in self-reported incontinence, stress testing for incontinence, or prolapse stage.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537085.001).
  • [ISSN] 0002-8614
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NICHD NIH HHS / HD / U10 HD041261; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41269; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NIDDK NIH HHS / DK / K24 DK068389; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U01 HD41249
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. David S, Kümpers P, Eisenbach GM, Haller H, Kielstein JT: Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrol Dial Transplant; 2009 Jul;24(7):2232-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, patients with end-stage renal disease are usually dialyzed only 12-15 h/ week.
  • CONCLUSION: This study demonstrates improvements in numerous dialysis-associated metabolic variables after intensification of HD time.
  • [MeSH-minor] Adult. Humans. Longitudinal Studies. Prospective Studies

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208770.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Lie PP, Xia W, Wang CQ, Mruk DD, Yan HH, Wong CH, Lee WM, Cheng CY: Dynamin II interacts with the cadherin- and occludin-based protein complexes at the blood-testis barrier in adult rat testes. J Endocrinol; 2006 Dec;191(3):571-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamin II interacts with the cadherin- and occludin-based protein complexes at the blood-testis barrier in adult rat testes.
  • In adult rat testes, blood-testis barrier (BTB) restructuring facilitates the migration of preleptotene spermatocytes from the basal to the adluminal compartment that occurs at stage VIII of the epithelial cycle.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170215.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD045908; United States / NICHD NIH HHS / HD / U54 HD029990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Hydrazines; 0 / Indazoles; 0 / Membrane Proteins; 0 / Occludin; 0 / Ocln protein, rat; 0 / Phosphoproteins; 0 / Tjp1 protein, rat; 0 / Zonula Occludens-1 Protein; 0 / beta Catenin; 0 / nectins; EC 3.6.5.5 / Dynamin II
  •  go-up   go-down


34. Lamm BM, Gottlieb HD, Paley D: A two-stage percutaneous approach to charcot diabetic foot reconstruction. J Foot Ankle Surg; 2010 Nov-Dec;49(6):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage percutaneous approach to charcot diabetic foot reconstruction.
  • Feet were operated on at various stages of Charcot deformity: Eichenholtz stage I (1 foot), Eichenholtz stage II (6 feet), and Eichenholtz stage III (4 feet).
  • [MeSH-minor] Achilles Tendon / surgery. Adult. Aged. Equinus Deformity / surgery. Female. Fluoroscopy. Foot Bones / surgery. Foot Joints / radiography. Foot Joints / surgery. Humans. Male. Middle Aged. Muscle, Skeletal / surgery

  • MedlinePlus Health Information. consumer health - Diabetic Foot.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20864361.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Moukeh G, Yacoub R, Fahdi F, Rastam S, Albitar S: Epidemiology of hemodialysis patients in Aleppo city. Saudi J Kidney Dis Transpl; 2009 Jan;20(1):140-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the characteristics of the hemodialysis (HD) patients in Aleppo city, we surveyed the hospitals representing the main dialysis centers in the city including private and community facilities during 2006.
  • The total number of patients in 2006 undergoing HD was 550 patients; 280 (50.9%) were males, and the age ranged from 5-82 years with mean and median age 44.7 and 45 years, respectively.
  • The major primary renal diseases in the end-stage renal disease (ESRD) patients included hypertension (HTN), glomerulonephritis (GN), and diabetes mellitus (DM), 21.1%, 20.5 %, and 19.45, respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Comorbidity. Cross-Sectional Studies. Female. Hepatitis B / epidemiology. Hepatitis C / epidemiology. Humans. Incidence. Male. Middle Aged. Prevalence. Syria / epidemiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112237.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


36. Sampson M, Archibong AE, Powell A, Strange B, Roberson S, Hills ER, Bourne P: Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea. Int J Environ Res Public Health; 2010 05;7(5):2033-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fourteen cases of HU therapy in pregnant patients diagnosed with acute or chronic myelogenous leukemia, primary thrombocythemia, or sickle cell disease (SCD) have been reported.
  • The objective of this study was to assess the risks associated with a clinically relevant dose of HU used for the treatment of SCD, on ovulation rate and embryo development, using adult C57BL/6J female mice as a model.
  • In Experiment 1, adult female mice were randomly assigned to a treatment or a control group (N = 20/group).
  • Ovulation was induced in the remaining mice at 48 hours post PMSG with human chorionic gonadotropin (hCG) and immediately caged with adult males for mating.
  • Fewer embryos retrieved from HU-treated mice developed to blastocyst stage (32%) compared with those from controls (60%; P < 0.05).
  • Furthermore, continuous or intermittent in vitro exposures of embryos to HU also resulted in reduced development to blastocyst stage (continuous HU, 9 vs. control, 63%; P < 0.05; intermittent HU, 20 vs. control, 62%; P < 0.05) with embryos exposed continuously to HU in vitro fairing worse.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 1987 May;36(4):890-8 [3109516.001]
  • [Cites] Biol Reprod. 1985 Jun;32(5):1069-79 [3926013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8925-8 [7692440.001]
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1132-6 [7700286.001]
  • [Cites] Genes Dev. 1996 Apr 15;10(8):934-47 [8608941.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):1021-30 [10099145.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1517-36 [10477676.001]
  • [Cites] Exp Toxicol Pathol. 2004 Oct;56(1-2):1-7 [15581269.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):1013-23 [15772364.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Nov;23(11):1360-5 [18184078.001]
  • [Cites] Int J Environ Res Public Health. 2009 Mar;6(3):1124-44 [19440437.001]
  • [Cites] Ann Hematol. 2009 Oct;88(10):967-71 [19214510.001]
  • [Cites] Environ Res. 2009 Oct;109(7):922-9 [19682677.001]
  • [Cites] Pharmacotherapy. 1999 Dec;19(12):1459-62 [10600098.001]
  • [Cites] Exp Gerontol. 2000 Aug;35(5):553-71 [10978678.001]
  • [Cites] Chemotherapy. 2001 Jul-Aug;47(4):270-8 [11399864.001]
  • [Cites] Reprod Toxicol. 2002 Nov-Dec;16(6):801-8 [12401509.001]
  • [Cites] Endocrinology. 1982 Dec;111(6):2077-86 [6291909.001]
  • [Cites] J Reprod Fertil. 1984 Sep;72(1):39-53 [6540808.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 9):1-10 [1641648.001]
  • (PMID = 20623009.001).
  • [ISSN] 1660-4601
  • [Journal-full-title] International journal of environmental research and public health
  • [ISO-abbreviation] Int J Environ Res Public Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD044315; United States / NICHD NIH HHS / HD / R01 HD020419-19S1; United States / NICHD NIH HHS / HD / 1U54HD044315; United States / NCRR NIH HHS / RR / G12 RR003032; United States / NCRR NIH HHS / RR / G12RR03032; United States / NICHD NIH HHS / HD / R01 HD020419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ PMC2898034
  • [Keywords] NOTNLM ; 2-cell embryo (major topic) / blastocyst (major topic) / estradiol-17β ovulation rate (major topic) / hydroxyurea (major topic) / ovarian weight (major topic)
  •  go-up   go-down


37. Weng CH, Hsu CW, Yu CC, Yen TH, Yang CW, Hung CC: Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. Kidney Blood Press Res; 2009;32(6):451-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study compared peritoneal dialysis (PD) and hemodialysis (HD) outcomes between female systemic lupus erythematosus (SLE) patients with end-stage renal disease (ESRD) due to lupus nephropathy.
  • METHODS: 22 female SLE patients undergoing PD were compared with 14 female SLE patients receiving HD.
  • RESULTS: The overall mortality rate was much higher in the PD group (6/22) than in the HD group (1/14) (p = 0.027).
  • HD: 1 episode per 33.16 patient-months vs. 1 episode per 118.26 patient-months, respectively, p = 0.046).
  • Before the end of the observation period, HD patients had higher serum albumin (3.8 +/- 0.2 vs. 3.3 +/- 0.6 g/dl, p = 0.01).
  • CONCLUSIONS: In female SLE patients with ESRD due to lupus nephropathy, clinical outcomes are better after undergoing HD than after undergoing PD.
  • [MeSH-minor] Adult. C-Reactive Protein / metabolism. Cause of Death. Female. Humans. Immunosuppressive Agents / therapeutic use. Infection / complications. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Serum Albumin / metabolism. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 20016213.001).
  • [ISSN] 1423-0143
  • [Journal-full-title] Kidney & blood pressure research
  • [ISO-abbreviation] Kidney Blood Press. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Serum Albumin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


38. Sahin G, Yalcin AU, Akcar N: Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients. Blood Purif; 2007;25(4):309-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Patients with K/DOQI stage 5 chronic kidney disease (CKD) have higher incidence of cardiovascular events due to the oxidative stress and endothelial dysfunction (ED).
  • METHODS: Thirty uremic patients (age 40 +/- 12 years, 6 males) on hemodialysis (HD) were evaluated for ED by using high-resolution Doppler ultrasound of brachial artery before and after 6 weeks of oral NAC (2 x 600 mg) medication.
  • RESULTS: Patients on HD had lower DeltaFMD (0.28 +/- 0.17 vs. 0.41 +/- 0.11, p < 0.05) and FMD% (7.5 +/- 5.05 vs. 11.33 +/- 2.95, p < 0.05) than the controls.
  • NAC treatment significantly increased the DeltaFMD (0.41 +/- 0.11, p < 0.001 vs. baseline) and FMD% (10.59 +/- 3.22, p < 0.01 vs. baseline) of patients on HD, while it had no effect on DeltaGTN and GTN%.
  • CONCLUSION: These results suggest that NAC treatment could improve the ED by preventing the reduction of FMD in patients on HD.
  • [MeSH-minor] Adult. Brachial Artery / drug effects. Brachial Artery / physiopathology. Brachial Artery / ultrasonography. Female. Hemorheology. Humans. Male. Middle Aged. Nitric Oxide / physiology. Nitroglycerin. Oxidative Stress / drug effects. Vasodilation / drug effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • [CommentIn] Blood Purif. 2008;26(4):354 [18487879.001]
  • (PMID = 17643057.001).
  • [ISSN] 1421-9735
  • [Journal-full-title] Blood purification
  • [ISO-abbreviation] Blood Purif.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 31C4KY9ESH / Nitric Oxide; G59M7S0WS3 / Nitroglycerin; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


39. Larsen U, Mlay J, Aboud S, Ballard R, Sam NE, Shao JF, Kapiga SH: Design of a community-based study of sexually transmitted infections/HIV and infertility in an urban area of northern Tanzania. Sex Transm Dis; 2007 Jan;34(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Households were selected using a 2-stage sampling design.
  • [MeSH-minor] Adult. Community Health Services. Epidemiologic Methods. Female. HIV Infections / blood. HIV Infections / epidemiology. HIV Infections / etiology. HIV Infections / prevention & control. HIV Infections / urine. Humans. Male. Prevalence. Research Design. Sexual Behavior. Surveys and Questionnaires. Tanzania / epidemiology. Urban Health Services


40. Miller JE, Hilliard AT, White SA: Song practice promotes acute vocal variability at a key stage of sensorimotor learning. PLoS One; 2010 Jan 06;5(1):e8592
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Song practice promotes acute vocal variability at a key stage of sensorimotor learning.
  • In juvenile and adult male zebra finches, endogenous levels of FoxP2, a molecule critical for language, decrease two hours after morning song onset within area X, part of the basal ganglia-forebrain pathway dedicated to song.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Aug 30;26(35):9010-4 [16943558.001]
  • [Cites] PLoS Biol. 2007 Dec;5(12):e321 [18052609.001]
  • [Cites] J Neurosci. 2006 Nov 15;26(46):11888-92 [17108162.001]
  • [Cites] J Neurobiol. 2006 Dec;66(14):1613-29 [17058190.001]
  • [Cites] Dev Sci. 2007 Jan;10(1):110-20 [17181708.001]
  • [Cites] Eur J Neurosci. 2006 Dec;24(12):3619-27 [17229110.001]
  • [Cites] Eur J Neurosci. 2007 Apr;25(7):2145-60 [17419760.001]
  • [Cites] Dev Neurobiol. 2007 May;67(6):809-17 [17443826.001]
  • [Cites] J Neurophysiol. 2007 Jun;97(6):4271-83 [17182906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17849-54 [17978184.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1144-57 [17999357.001]
  • [Cites] Nat Rev Neurosci. 2000 Oct;1(1):31-40 [11252766.001]
  • [Cites] J Comp Psychol. 2001 Jun;115(2):172-80 [11459164.001]
  • [Cites] Nature. 2001 Oct 4;413(6855):519-23 [11586359.001]
  • [Cites] Behav Brain Res. 2002 Apr 1;131(1-2):57-65 [11844572.001]
  • [Cites] J Neurosci. 2002 May 1;22(9):3776-87 [11978853.001]
  • [Cites] Nature. 2002 Sep 5;419(6902):65-70 [12214232.001]
  • [Cites] J Neurophysiol. 2002 Oct;88(4):1903-14 [12364516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):8030-5 [12808137.001]
  • [Cites] J Neurosci. 2004 Mar 31;24(13):3152-63 [15056695.001]
  • [Cites] J Neurosci. 2004 Mar 31;24(13):3164-75 [15056696.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1016:325-47 [15313783.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1016:749-77 [15313804.001]
  • [Cites] Science. 1984 May 25;224(4651):901-3 [6719123.001]
  • [Cites] Behav Neural Biol. 1990 Jan;53(1):51-63 [2302141.001]
  • [Cites] Dev Med Child Neurol. 1990 Apr;32(4):352-5 [2332125.001]
  • [Cites] Am J Hum Genet. 2008 Jan;82(1):150-9 [18179893.001]
  • [Cites] J Neurophysiol. 2008 Apr;99(4):1700-11 [18216221.001]
  • [Cites] J Neurosci. 2008 Oct 8;28(41):10370-9 [18842896.001]
  • [Cites] J Neurophysiol. 2008 Oct;100(4):2015-25 [18701760.001]
  • [Cites] J Neurophysiol. 2008 Nov;100(5):2956-65 [18784276.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2337-45 [18987363.001]
  • [Cites] J Neurosci. 2009 Apr 15;29(15):4782-93 [19369547.001]
  • [Cites] J Neurophysiol. 2009 Oct;102(4):2485-97 [19692513.001]
  • [Cites] J Chem Neuroanat. 2010 Mar;39(2):124-31 [19596062.001]
  • [Cites] Nat Neurosci. 2000 Apr;3(4):377-83 [10725928.001]
  • [Cites] J Neurosci. 1991 Sep;11(9):2896-913 [1880555.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1871-5 [8791594.001]
  • [Cites] Neuron. 1997 Feb;18(2):315-25 [9052801.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4097-102 [9108111.001]
  • [Cites] Neuron. 1997 Nov;19(5):1049-59 [9390518.001]
  • [Cites] J Comp Neurol. 1998 Apr 20;393(4):426-38 [9550149.001]
  • [Cites] Neuron. 1998 Oct;21(4):775-88 [9808464.001]
  • [Cites] J Comp Neurol. 1999 Jan 5;403(1):68-84 [10075444.001]
  • [Cites] Annu Rev Neurosci. 1999;22:567-631 [10202549.001]
  • [Cites] J Neurosci. 1999 Aug 1;19(15):6700-11 [10414999.001]
  • [Cites] Nat Rev Neurosci. 2005 Feb;6(2):131-8 [15685218.001]
  • [Cites] Nat Rev Neurosci. 2005 Feb;6(2):151-9 [15685220.001]
  • [Cites] Nature. 2005 Feb 10;433(7026):638-43 [15703748.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):710-6 [15716944.001]
  • [Cites] J Comp Neurol. 2005 Mar 28;484(1):93-104 [15717304.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):127-32 [15749165.001]
  • [Cites] J Neurophysiol. 2005 Apr;93(4):1871-9 [15548618.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(7):1962-72 [15869489.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(7):1667-78 [16197507.001]
  • [Cites] Nature. 2005 Oct 20;437(7062):1158-61 [16237445.001]
  • [Cites] J Neurobiol. 2005 Dec;65(3):251-9 [16155900.001]
  • [Cites] Curr Opin Neurobiol. 2005 Dec;15(6):638-44 [16271465.001]
  • [Cites] J Neurosci. 2006 Jul 12;26(28):7390-4 [16837586.001]
  • [Cites] J Neurophysiol. 2006 Sep;96(3):1441-55 [16723412.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1232-50 [17999362.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1240-4 [18097411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15212-7 [17018643.001]
  • (PMID = 20066039.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / 2T32 MH019384-11A2; United States / NIMH NIH HHS / MH / R01 MH070712; United States / NICHD NIH HHS / HD / T32 HD007032; United States / NIMH NIH HHS / MH / R01 MH070712-05; United States / NIMH NIH HHS / MH / 1F31 MH082533-01A1; United States / NIMH NIH HHS / MH / T32 MH019384; United States / NIMH NIH HHS / MH / F31 MH082533; United States / NICHD NIH HHS / HD / T32 HD0007032; United States / NIMH NIH HHS / MH / 1R01 MH070712
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2797613
  •  go-up   go-down


41. Macías Núñez JF, Ghais Z, Bustamante J, Lopez-Novoa JM, Arrieta J, Barril G, Del Pino MD, Escaja C, Martín IM, Fernández Andrade C, García F, Núñez J, Onaindía JM, González J, Pérez-Prieto M, Fernández M, Lopez J, Santiago JM, Vicens M, Sousa F: Evaluation of oxidant-antioxidant balance in patients on maintenance haemodialysis: a comparative study of dialyzers membranes. Nephron Clin Pract; 2010;114(1):c67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Haemodialysis (HD) exacerbates oxidative stress (OS).
  • AIM: To compare OS and inflammatory status in HD-treated end stage renal disease patients with membranes of different pore size radius and flux.
  • The HD membranes with which the patients were normally treated were changed to BK-P or B-3 membranes for 6 months.
  • CONCLUSION: BK-P and B-3 HD membranes improved the OAB, beta2mu-globulin and CRP compared to PAN/AN69 and cellulose diacetate membranes.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / analysis. Comorbidity. Equipment Design. Female. Humans. Male. Middle Aged. Serum Albumin / analysis. Superoxide Dismutase / metabolism. Transferrin / analysis. beta 2-Microglobulin / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19816045.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Membranes, Artificial; 0 / Serum Albumin; 0 / Transferrin; 0 / beta 2-Microglobulin; 9007-41-4 / C-Reactive Protein; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


42. Civilibal M, Oflaz H, Caliskan S, Candan C, Canpolat N, Pehlivan G, Sever L, Kasapcopur O, Arisoy N: Left ventricular systolic and diastolic function and carotid intima-media thickness in pediatric dialysis patients. Int Urol Nephrol; 2009;41(2):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cardiovascular complications are common in patients with end-stage renal disease (ESRD).
  • Compared with PD patients, HD patients had worse LV diastolic function.
  • [MeSH-minor] Adolescent. Cardiovascular Diseases / etiology. Case-Control Studies. Child. Female. Humans. Male. Risk Factors. Tunica Intima / diagnostic imaging. Tunica Intima / pathology. Tunica Media / diagnostic imaging. Tunica Media / pathology. Ultrasonography. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1918-27 [12089389.001]
  • [Cites] Pediatr Transplant. 2001 Aug;5(4):279-84 [11472607.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14 (10-11):898-902 [10975295.001]
  • [Cites] Kidney Int. 1996 Sep;50(3):998-1006 [8872976.001]
  • [Cites] Pediatr Nephrol. 2007 Jan;22(1):109-16 [16944211.001]
  • [Cites] J Am Coll Cardiol. 1992 Nov 1;20(5):1251-60 [1401629.001]
  • [Cites] Pediatr Nephrol. 2005 Mar;20(3):374-9 [15549413.001]
  • [Cites] Heart Vessels. 2004 Jul;19(4):189-95 [15278393.001]
  • [Cites] J Am Coll Cardiol. 1995 Apr;25(5):1056-62 [7897116.001]
  • [Cites] Perit Dial Int. 1997 Jul-Aug;17(4):353-9 [9284462.001]
  • [Cites] Acta Paediatr. 2005 Aug;94(8):1055-9 [16188849.001]
  • [Cites] Pediatr Nephrol. 2006 Oct;21(10 ):1426-33 [16821026.001]
  • [Cites] Pediatr Nephrol. 2008 Jan;23(1):27-39 [17120060.001]
  • [Cites] Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9 [9820470.001]
  • [Cites] Kidney Int Suppl. 2005 Jan;(93):S35-8 [15613066.001]
  • [Cites] Am J Cardiol. 1986 Feb 15;57(6):450-8 [2936235.001]
  • [Cites] Kidney Int Suppl. 2005 Jan;(93):S39-43 [15613067.001]
  • [Cites] J Pediatr. 2002 Aug;141(2):191-7 [12183713.001]
  • [Cites] Circulation. 2004 Jul 6;110(1):97-101 [15210594.001]
  • [Cites] Pediatr Nephrol. 1993 Dec;7(6):725-8 [8130091.001]
  • [Cites] J Am Soc Nephrol. 2005 May;16(5):1494-500 [15772249.001]
  • [Cites] Pediatr Int. 2002 Feb;44(1):18-23 [11982865.001]
  • [Cites] N Engl J Med. 2000 May 18;342(20):1478-83 [10816185.001]
  • [Cites] J Am Soc Nephrol. 2005 Sep;16(9):2796-803 [16049067.001]
  • [Cites] Nephrol Dial Transplant. 1990;5(6):426-31 [2122318.001]
  • [Cites] Pediatr Nephrol. 2007 Jul;22(7):1021-9 [17340147.001]
  • [Cites] Int Urol Nephrol. 2008;40(2):497-502 [18085423.001]
  • [Cites] Circulation. 2002 Jul 2;106(1):100-5 [12093777.001]
  • [Cites] J Hypertens. 2005 Sep;23 (9):1707-15 [16093916.001]
  • (PMID = 18690547.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


43. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC: Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int; 2007 Jan;71(2):153-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Considerable geographic variation exists in the relative use of hemodialysis (HD) vs peritoneal dialysis (PD).
  • Our aim was to compare the survival of Dutch HD and PD patients.
  • We developed Cox regression models using 16 643 patients from the Dutch End-Stage Renal Disease Registry (RENINE) adjusting for age, gender, primary renal disease, center of dialysis, year of start of renal replacement therapy, and included several interaction terms.
  • For the first period, the mortality hazard ratio (HR) of PD compared with HD patients was 0.26 (95% confidence interval (CI) 0.17-0.41) for 40-year-old non-diabetics, which increased with age and presence of diabetes to 0.95 (95% CI 0.64-1.39) for 70-year-old patients with diabetes as primary renal disease.
  • After 15 months, the HR was 0.86 (95% CI 0.74-1.00) for 40-year-old non-diabetics and 1.42 (95% CI 1.23-1.65) for 70-year-old patients with diabetes as primary renal disease.
  • We conclude that the survival advantage for Dutch PD compared with HD patients decreases over time, with age and in the presence of diabetes as primary disease.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Netherlands / epidemiology. Proportional Hazards Models. Survival Analysis


44. Thanakitcharu P, Siriwiwatanakul N: Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. J Med Assoc Thai; 2007 Dec;90(12):2574-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anemia is common in end-stage renal disease (ESRD) patients and an important determinant for left ventricular hypertrophy (LVH) in dialysis patients.
  • MATERIAL AND METHOD: Twenty-two hemodialysis (HD) subjects were recruited from Rajavithi and Huachiew Hospitals.
  • Inclusion criteria were chronic HD, hemoglobin (Hb) < 10 g/dL without preceding treatment (epoetin or transfusion) for 1 month.
  • [MeSH-minor] Adult. Aged. Epoetin Alfa. Female. Health Status Indicators. Heart Ventricles / drug effects. Heart Ventricles / physiopathology. Heart Ventricles / ultrasonography. Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Middle Aged. Prospective Studies. Recombinant Proteins. Time Factors

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386706.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa
  •  go-up   go-down


45. Cheng YW, Hopkins LM, Laros RK Jr, Caughey AB: Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes. Am J Obstet Gynecol; 2007 Jun;196(6):585.e1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes.
  • OBJECTIVE: This study was undertaken to examine perinatal outcomes associated with the second stage of labor in multiparous women.
  • Duration of the second stage of labor was stratified into hourly intervals: 0-1 hour, 1-2 hours, 2-3 hours, and 3 hours or longer.
  • RESULTS: Compared with women who delivered between the 0- and 2-hour interval, women with a second stage more than 3 hours had higher risks of operative vaginal deliveries (odds ratio = 13.27; 95% CI [9.38-18.8]), cesarean deliveries (odds ratio = 6.00; [4.06-8.86]), and maternal morbidity including third- or fourth-degree perineal lacerations, postpartum hemorrhage, and chorioamnionitis.
  • CONCLUSION: Multiparous women with a second stage of 3 hours or greater are at increased risks for operative deliveries, peripartum morbidity, and undesirable neonatal outcomes.
  • These outcomes should be considered in the management of multiparous women with a second stage of labor beyond 3 hours.
  • [MeSH-major] Labor Stage, Second. Parity
  • [MeSH-minor] Adult. Apgar Score. California / epidemiology. Cesarean Section / statistics & numerical data. Chorioamnionitis / epidemiology. Cohort Studies. Endometritis / epidemiology. Extraction, Obstetrical / statistics & numerical data. Female. Humans. Hydrogen-Ion Concentration. Infant, Newborn. Intensive Care Units, Neonatal. Length of Stay / statistics & numerical data. Meconium. Multivariate Analysis. Patient Admission / statistics & numerical data. Perineum / injuries. Postpartum Hemorrhage / epidemiology. Pregnancy. Retrospective Studies. Time Factors. Umbilical Arteries / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547906.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD01262
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


46. Watkins AJ, Papenbrock T, Fleming TP: The preimplantation embryo: handle with care. Semin Reprod Med; 2008 Mar;26(2):175-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Attention has been drawn to the preimplantation stage of development as a sensitive "window" when in vitro and in vivo manipulations, such as culture conditions or maternal diet, may have critical consequences.
  • We consider how fetal and postnatal phenotype may become susceptible to the plasticity of the preimplantation embryo and the risks for adult health and physiology.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302109.001).
  • [ISSN] 1526-8004
  • [Journal-full-title] Seminars in reproductive medicine
  • [ISO-abbreviation] Semin. Reprod. Med.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/F007450/1; United Kingdom / Medical Research Council / / G0100558; United Kingdom / Biotechnology and Biological Sciences Research Council / / G18784; United States / NICHD NIH HHS / HD / U01 HD044635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 145
  •  go-up   go-down


47. Gençöz F, Gençöz T, Soykan A: Psychometric properties of the Hamilton Depression Rating Scale and other physician-rated psychiatric scales for the assessment of depression in ESRD patients undergoing hemodialysis in Turkey. Psychol Health Med; 2007 Aug;12(4):450-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to examine the reliability and validity of clinician-rated psychiatric scales for end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) treatment in Turkey.
  • For this, the Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Global Assessment of Functioning (GAF) Scale, Clinical Global Impression (CGI) Scale, and Mini Mental State Exam (MMSE) were administered to 45 ESRD outpatients undergoing HD treatment.
  • In general, the findings of this study indicate that HDRS, HARS, CGI, GAF, and MMSE are reliable and valid instruments that can be used among ESRD patients undergoing HD.
  • [MeSH-minor] Adult. Aged. Cognition Disorders / diagnosis. Cognition Disorders / epidemiology. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Observer Variation. Physicians. Psychometrics. Renal Dialysis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620209.001).
  • [ISSN] 1354-8506
  • [Journal-full-title] Psychology, health & medicine
  • [ISO-abbreviation] Psychol Health Med
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


48. Teichmann M, Dupoux E, Kouider S, Bachoud-Lévi AC: The role of the striatum in processing language rules: evidence from word perception in Huntington's disease. J Cogn Neurosci; 2006 Sep;18(9):1555-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the striatum in processing language rules: evidence from word perception in Huntington's disease.
  • The model of Huntington's disease at early stage.
  • We investigated these issues by assessing perceptive processing of conjugated verb forms in a model of striatal dysfunction, namely, in Huntington's Disease (HD) at early stages.
  • HD patients were also assessed in executive functions, and striatal atrophy was evaluated with magnetic resonance imaging (bicaudate ratio).
  • Results from both tasks showed that HD patients were selectively impaired for rule application but lexical abilities were spared.
  • [MeSH-major] Corpus Striatum / physiology. Huntington Disease / physiopathology. Mental Processes / physiology. Speech Perception / physiology. Verbal Behavior / physiology
  • [MeSH-minor] Adult. Atrophy. Female. Humans. Language Disorders / complications. Language Disorders / pathology. Language Disorders / physiopathology. Linguistics. Male. Middle Aged. Reference Values. Severity of Illness Index. Speech Discrimination Tests

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989555.001).
  • [ISSN] 0898-929X
  • [Journal-full-title] Journal of cognitive neuroscience
  • [ISO-abbreviation] J Cogn Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Sanchez AR, Madonia C, Rascon-Pacheco RA: Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory peritoneal dialysis in a Mexican PD center. Kidney Int Suppl; 2008 Apr;(108):S76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data at the beginning of therapy, causes of end-stage renal disease, gender, age, dialysis modality, drop out reasons, as well as peritonitis rate and date of presentation of first peritonitis event were collected and analyzed.
  • The CAPD drop out causes were death (57%), transfer to HD (29%), and other causes (16%), whereas in APD, 62% were due to death, 24% to transfer to HD, and 14% to other causes.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Male. Mexico. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379553.001).
  • [ISSN] 0098-6577
  • [Journal-full-title] Kidney international. Supplement
  • [ISO-abbreviation] Kidney Int. Suppl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. McConkie-Rosell A, Heise EM, Spiridigliozzi GA: Genetic risk communication: experiences of adolescent girls and young women from families with fragile X syndrome. J Genet Couns; 2009 Aug;18(4):313-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this void, we explored how genetic risk information was learned, what information was given and who primarily provided information to adolescent girls and young adult women in families with fragile X syndrome.
  • The content of the remembered conversations varied based on the stage of genetic risk information being disclosed as well as the girls' knowledge of her own carrier status.

  • Genetic Alliance. consumer health - Fragile X Syndrome.
  • Genetic Alliance. consumer health - Young syndrome.
  • MedlinePlus Health Information. consumer health - Fragile X Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 2000 Jun 19;92(5):336-42 [10861663.001]
  • [Cites] Am J Med Genet A. 2009 Jun;149A(6):1190-9 [19449413.001]
  • [Cites] Am J Med Genet. 2001 Jan 1;98(1):37-45 [11426454.001]
  • [Cites] Am J Med Genet. 2000 Fall;97(3):189-94 [11449487.001]
  • [Cites] Hum Mol Genet. 2002 Feb 15;11(4):371-8 [11854169.001]
  • [Cites] Am J Med Genet. 2002 Jun 1;110(1):36-44 [12116269.001]
  • [Cites] Am J Med Genet. 2002 Jul 1;110(3):226-33 [12116230.001]
  • [Cites] Patient Educ Couns. 2002 Jun;47(2):145-53 [12191538.001]
  • [Cites] Fam Process. 2003 Spring;42(1):1-18 [12698595.001]
  • [Cites] Clin Genet. 2003 Oct;64(4):317-26 [12974737.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):805-16 [15052536.001]
  • [Cites] Am J Hum Genet. 1995 Nov;57(5):1006-18 [7485149.001]
  • [Cites] Am J Med Genet. 1995 Dec 4;59(4):426-30 [8585560.001]
  • [Cites] Am J Med Genet. 1996 Jul 12;64(1):196-7 [8826475.001]
  • [Cites] Am J Med Genet. 1997 Jan 10;68(1):62-9 [8986278.001]
  • [Cites] J Med Genet. 1997 Jan;34(1):1-5 [9032640.001]
  • [Cites] Patient Educ Couns. 2004 Dec;55(3):363-70 [15582342.001]
  • [Cites] Health Educ Behav. 2005 Oct;32(5):627-39 [16148209.001]
  • [Cites] J Genet Couns. 2006 Aug;15(4):253-65 [16850280.001]
  • [Cites] Genet Test. 2007 Fall;11(3):249-55 [17949286.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2008 Feb 15;148C(1):56-69 [18200514.001]
  • [Cites] J Genet Couns. 2008 Aug;17(4):327-35 [18347962.001]
  • [Cites] Psychooncology. 2009 Feb;18(2):200-8 [18702049.001]
  • [Cites] Patient Educ Couns. 2001 Mar;42(3):213-24 [11164320.001]
  • (PMID = 19277853.001).
  • [ISSN] 1573-3599
  • [Journal-full-title] Journal of genetic counseling
  • [ISO-abbreviation] J Genet Couns
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R03 HD044647; United States / NICHD NIH HHS / HD / HD044647-02; United States / NICHD NIH HHS / HD / 5R03HD044647-02.; United States / NICHD NIH HHS / HD / R03 HD044647-01A1; United States / NICHD NIH HHS / HD / HD044647-01A1; United States / NICHD NIH HHS / HD / R03 HD044647-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS112818; NLM/ PMC2756689
  •  go-up   go-down


51. Su LH, Wu KD, Lee LS, Wang H, Liu CF: Effects of far infrared acupoint stimulation on autonomic activity and quality of life in hemodialysis patients. Am J Chin Med; 2009;37(2):215-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It also stimulates autonomic nervous system (ANS) activity in patients who are diagnosed with end-stage renal disease (ESRD) and are receiving regular hemodialysis (HD).
  • [MeSH-minor] Adult. Female. Humans. Hyperthermia, Induced. Male. Middle Aged


52. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA: Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis; 2010 Sep;31(9):1597-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unconditional logistic regression models assessed the relationship between each SNP and incident advanced stage (T(3)/T(4), T(0)-T(4)/M(1) and lethal disease) and high Gleason grade (>/=7) prostate cancer.
  • Missense mutations R462Q and D541E were associated with an increased risk of advanced stage disease only in the pre-prostate-specific antigen era.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2002 Feb;30(2):181-4 [11799394.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):588-99 [20086112.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):581-3 [12415269.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):691-6 [12915880.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26 [8757191.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1371-4 [8910276.001]
  • [Cites] EMBO J. 1997 Nov 3;16(21):6355-63 [9351818.001]
  • [Cites] J Urol. 1999 Jan;161(1):182-7 [10037394.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9144-51 [15604285.001]
  • [Cites] Ann Intern Med. 2005 Mar 15;142(6):425-32 [15767620.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):949-57 [15824169.001]
  • [Cites] BJU Int. 2005 May;95(7):961-2 [15839913.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Prostate. 2006 Jan 1;66(1):49-56 [16114055.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e25 [16609730.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5713-9 [17020975.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Prostate. 2007 Jun 1;67(8):849-54 [17407163.001]
  • [Cites] Urol Int. 2007;79(1):44-9 [17627168.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):381-8 [17681844.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5959-64 [17908993.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):354-9 [18189233.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]
  • [Cites] Infect Genet Evol. 2008 May;8(3):297-301 [18295551.001]
  • [Cites] Cancer. 2008 Jun;112(11):2377-83 [18428198.001]
  • [Cites] Prostate. 2008 Sep 15;68(13):1416-20 [18615538.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):277-83 [18823818.001]
  • [Cites] Prostate. 2008 Dec 1;68(16):1790-7 [18767027.001]
  • [Cites] Breast Cancer Res Treat. 2009 Mar;114(1):155-67 [18401703.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2683-9 [19189403.001]
  • [Cites] Prostate. 2009 Jun 1;69(8):874-85 [19267370.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2137-44 [19567509.001]
  • [Cites] Cancer Causes Control. 2009 Sep;20(7):1193-203 [19267250.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1122-6 [19767754.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1055-7 [19767755.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):981-4 [12145743.001]
  • (PMID = 20576793.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-40360; United States / NCI NIH HHS / CA / CA-34944; United States / NHLBI NIH HHS / HL / HL-34595; United States / NHLBI NIH HHS / HL / HL-26490; United States / NCI NIH HHS / CA / T32 CA-09001; United States / NCI NIH HHS / CA / CA-058684; United States / NCI NIH HHS / CA / CA-097193; United States / NCI NIH HHS / CA / R01 CA097193
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-6; 9007-41-4 / C-Reactive Protein; EC 3.1.- / Endoribonucleases; EC 3.1.26.- / 2-5A-dependent ribonuclease
  • [Other-IDs] NLM/ PMC2930803
  •  go-up   go-down


53. Delval A, Krystkowiak P, Blatt JL, Labyt E, Dujardin K, Destée A, Derambure P, Defebvre L: Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study. J Neurol; 2006 Jan;253(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study.
  • OBJECTIVE: To evaluate specific patterns of locomotion in Huntington's disease (HD) and notably the respective roles of hypokinesia (i. e. a decrease in the amplitude of movement) and bradykinesia (i. e. difficulty in executing a movement, slowness) in gait disturbance.
  • METHODS: Kinematic, spatial (stride length, speed), temporal (cadence, speed, and stride time) and angular gait parameters (joint ankle range) were recorded in 15 early-stage HD patients by means of a video motion analysis system and then compared with 15 controls and 15 Parkinson's disease (PD) patients.
  • RESULTS: we observed a clear decrease in gait speed, a decrease in cadence and an increase in stride time (i. e. bradykinesia) for HD, with significant intra-individual variability.
  • In HD, there was no evidence for a clear decrease in stride length, although the latter is a characteristic feature of hypokinetic gait (such as that observed in PD).
  • Angle analysis revealed the coexistence of hyperkinesia and hypokinesia in HD, which thus participate in gait abnormalities.
  • Gait speed in HD was correlated to the motor part of the UHDRS.
  • CONCLUSION: Gait in HD is mainly characterized by a timing disorder: bradykinesia was present, with severe intra-individual variability in temporal gait parameters.
  • [MeSH-major] Gait Disorders, Neurologic / etiology. Huntington Disease / complications. Hyperkinesis / physiopathology. Hypokinesia / physiopathology
  • [MeSH-minor] Adult. Analysis of Variance. Biomechanical Phenomena / methods. Female. Humans. Joints / physiopathology. Male. Middle Aged. Neurologic Examination / methods. Parkinson Disease / physiopathology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • MedlinePlus Health Information. consumer health - Walking Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1992 Jun;42(6):1232-8 [1534875.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):63-4 [7537410.001]
  • [Cites] Arch Neurol. 2003 Jan;60(1):80-4 [12533092.001]
  • [Cites] Mov Disord. 1990;5(2):93-9 [2139171.001]
  • [Cites] Brain. 1994 Oct;117 ( Pt 5):1169-81 [7953597.001]
  • [Cites] J Neurol. 2001 Nov;248(11):944-9 [11757957.001]
  • [Cites] Alzheimer Dis Assoc Disord. 1997 Sep;11(3):132-9 [9305498.001]
  • [Cites] Ann Neurol. 1990 Apr;27(4):357-65 [1972318.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):398-403 [8401589.001]
  • [Cites] Neurology. 2003 Oct 28;61(8):1085-92 [14581669.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1532-4 [7798986.001]
  • [Cites] Mov Disord. 1999 May;14 (3):398-403 [10348461.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Mov Disord. 2002 Jan;17(1):76-83 [11835442.001]
  • [Cites] Brain. 2000 Sep;123 ( Pt 9):1767-83 [10960043.001]
  • [Cites] Mov Disord. 1999 Sep;14(5):808-19 [10495043.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):452-8 [10668713.001]
  • [Cites] Adv Neurol. 1984;40:375-9 [6695614.001]
  • [Cites] Mov Disord. 1995 Jul;10(4):472-81 [7565829.001]
  • [Cites] Neurology. 1985 Oct;35(10):1450-4 [3162109.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jan;80(1):59-65 [9915373.001]
  • [Cites] Adv Neurol. 2001;87:375-85 [11347241.001]
  • [Cites] Mov Disord. 1996 Jul;11(4):384-8 [8813217.001]
  • [Cites] Mov Disord. 1998 May;13(3):428-37 [9613733.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] J Neurol Sci. 1976 Aug;28(4):401-25 [133209.001]
  • [Cites] Brain. 1993 Oct;116 ( Pt 5):1201-22 [7693298.001]
  • (PMID = 16096818.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Shelbourne P, Coote E, Dadak S, Cobb SR: Normal electrical properties of hippocampal neurons modelling early Huntington disease pathogenesis. Brain Res; 2007 Mar 30;1139:226-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Normal electrical properties of hippocampal neurons modelling early Huntington disease pathogenesis.
  • Huntington disease (HD) is a neurodegenerative disorder caused by an unstable and progressive expansion of a CAG trinucleotide repeat tract in the HD gene.
  • Previous studies using truncated forms of the HD gene have shown pronounced deficits in synaptic transmission and plasticity but rather modest changes in intrinsic cellular properties, despite overt pathology.
  • The knock-in mice carrying a 72-80 CAG repeat mutation is an accurate genetic model of early stage HD, displaying a more subtle disease phenotype.
  • To relate full-length HD gene expression and differential polyglutamine expansion with possible pathophysiological changes in salient electrophysiological properties of neurons that may underlie early symptoms of HD, including mood and cognitive impairments, we have conducted whole-cell recordings from hippocampal area CA1 pyramidal cells in Hdh6/Q72 and Hdh4/Q80 knock-in mice.
  • Electrophysiological characterisation of cells obtained from young adult (<4 months) HD mice harbouring an expanded CAG repeat stretch and age-matched wild type (WT) mice revealed no significant differences in any of the active or passive membrane properties investigated.
  • Similar findings, showing a lack of significant differences in cellular electrical properties, were obtained from cells of aged (>18 months) HD mice and WT controls, despite modest levels of repeat length variability demonstrated by single cell PCR.
  • Thus, the current study indicates a lack of overt changes in the electrical membrane properties of pyramidal cells in HD mice accurately modelling early stage HD pathology.
  • Furthermore, together with our previous work, these findings point to a synaptic rather than cellular locus of HD-related pathology.
  • [MeSH-major] Hippocampus / physiology. Huntington Disease / physiopathology. Membrane Potentials / physiology. Pyramidal Cells / physiology
  • [MeSH-minor] Analysis of Variance. Animals. Disease Models, Animal. Electrophysiology. Matched-Pair Analysis. Mice. Mice, Neurologic Mutants. Mice, Transgenic. Patch-Clamp Techniques. Trinucleotide Repeat Expansion / physiology


55. Stefan M, Ji H, Simmons RA, Cummings DE, Ahima RS, Friedman MI, Nicholls RD: Hormonal and metabolic defects in a prader-willi syndrome mouse model with neonatal failure to thrive. Endocrinology; 2005 Oct;146(10):4377-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesize that a fetal developmental abnormality in PWS leads to the neonatal phenotype, whereas the adult phenotype results from a failure in compensatory mechanisms.
  • To address this hypothesis and better characterize the neonatal failure to thrive phenotype during postnatal life, we studied a transgenic deletion PWS (TgPWS) mouse model that shares similarities with the first stage of the human syndrome.
  • [MeSH-minor] Aging / physiology. Animals. Animals, Newborn. Body Weight. DNA Primers. Disease Models, Animal. Exons. Failure to Thrive. Fetus. Gene Deletion. Glucagon / blood. Insulin / blood. Liver Glycogen / metabolism. Mice. Mice, Transgenic. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Hormones.
  • MedlinePlus Health Information. consumer health - Prader-Willi Syndrome.
  • Hazardous Substances Data Bank. GLUCAGON .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002520.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG20898; United States / NIDDK NIH HHS / DK / DK19525; United States / NIDDK NIH HHS / DK / DK49210; United States / NIDDK NIH HHS / DK / DK53109; United States / NIDDK NIH HHS / DK / DK55704; United States / NIDDK NIH HHS / DK / DK61516; United States / NICHD NIH HHS / HD / HD31491; United States / NICHD NIH HHS / HD / HD36079
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hormones; 0 / Insulin; 0 / Liver Glycogen; 9007-92-5 / Glucagon
  •  go-up   go-down


56. Whitlock KE, Illing N, Brideau NJ, Smith KM, Twomey S: Development of GnRH cells: Setting the stage for puberty. Mol Cell Endocrinol; 2006 Jul 25;254-255:39-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of GnRH cells: Setting the stage for puberty.
  • Cells containing gonadotropin-releasing hormone (GnRH) are essential not only for reproduction but also for neuromodulatory functions in the adult animal.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777316.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / DC0421801; United States / NICHD NIH HHS / HD / HD050820
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 81
  •  go-up   go-down


57. Cheong JW, Park SY, Roh JK, Suh CO, Hahn JS: Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea. Yonsei Med J; 2006 Aug 31;47(4):455-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.
  • Hodgkin's disease (HD) is a hematologic malignancy which shows common features regardless of race, but racial differences may be considered with certain clinical characteristics.
  • HD in Korea shows somewhat different characteristics when compared to cases in Western countries.
  • We evaluated the clinical and histopathologic characteristics of HD, the outcomes of various chemotherapy regimens, and prognostic factors of HD in Korea.
  • One hundred and five patients with initial histopathologic diagnosis of Hodgkin's disease were retrospectively reviewed 20 years after diagnosis at Yonsei University College of Medicine.
  • The disease-free survival (DFS) and overall survival (OS) rate were 79.2% and 84.8% at 5-years, 70% and 79.2% at 10- and 20-years.
  • Univariate analysis revealed that age, B-symptom, ECOG scale, Ann Arbor stage, international prognostic index, and serum beta2-microglobulin level were significant prognostic factors for both DFS and OS.
  • In conclusion, the survival rates of HD patients in our center were superior to those of previous reports in Korea and Western countries.
  • Considering the higher OS rate and decreased incidence of side effects, the ABVD regimen may be recommended for the initial treatment of Hodgkin's disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Korea. Male. Middle Aged. Prognosis. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:105-10 [1280463.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):859-65 [1555977.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):19-26 [9440718.001]
  • [Cites] Eur J Cancer. 2005 May;41(7):998-1006 [15862748.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6400-8 [16155026.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:81-5 [10707785.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Ann Intern Med. 1970 Dec;73(6):881-95 [5525541.001]
  • [Cites] Cancer. 1975 Oct;36(4):1241-9 [1100220.001]
  • [Cites] Cancer. 1975 Jul;36(1):252-9 [54209.001]
  • [Cites] Cancer Treat Rep. 1982 Mar;66(3):439-49 [7060033.001]
  • [Cites] Cancer Treat Rev. 1982 Mar;9(1):21-35 [6175409.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):881-7 [6176323.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):739-46 [2422994.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1295-306 [3528400.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1713-9 [3651998.001]
  • [Cites] Ann Intern Med. 1991 Mar 1;114(5):361-5 [1992877.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1409-20 [1712836.001]
  • [Cites] Ann Hematol. 1993 Mar;66(3):139-40 [7682448.001]
  • (PMID = 16941733.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2687724
  •  go-up   go-down


58. Ucmak H, Kokoglu OF, Hosoglu S, Dogan E, Sayarlioglu H, Kuzhan N, Isik IO: Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail; 2008;30(2):227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Hepatitis C virus (HCV) is prevalent in hemodialysis (HD) patients.
  • The aim of the present study was to evaluate the long-term efficacy of pegylated interferon (PEG-IFNalpha-2a) in HCV-positive hemodialysis (HD) patients.
  • All patients underwent chronic hemodialysis treatment for end-stage renal disease during the study period.
  • Our results are encouraging for the administration of PEG-IFN alpha-2a in HCV-positive HD patients waiting for kidney transplantation.
  • [MeSH-minor] Adult. Case-Control Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Injections, Subcutaneous. Kidney Function Tests. Long-Term Care. Male. Middle Aged. Recombinant Proteins. Reference Values. Risk Assessment. Serologic Tests. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ren Fail. 2008;30(3):343. Ucmaky, Hasan [corrected to Ucmak, Hasan]; Kokoglu, Omer Faruk [corrected to Kokoglu, Omer Faruk]
  • (PMID = 18300126.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


59. Ozdogan O, Kayikcioglu M, Asci G, Ozkahya M, Toz H, Sezis M, Can LH, Ok E: Left atrial volume predicts mortality in low-risk dialysis population on long-term low-salt diet. Am Heart J; 2010 Jun;159(6):1089-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Echocardiography provides insight to the management of end-stage renal disease (ESRD) and might be valuable in assessing the prognosis.
  • We evaluated the predictive value of echocardiography along with clinical findings in a low-risk hemodialysis (HD) population who had been treated with strict salt restriction strategy for blood pressure control.
  • METHODS: Study population consisted of a cohort of 555 ESRD patients from 8 HD centers where the same strict volume control strategy applied for blood pressure control.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure / physiology. Echocardiography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate / trends. Time Factors. Turkey / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20569724.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


60. Simorangkir DR, Marshall GR, Ehmcke J, Schlatt S, Plant TM: Prepubertal expansion of dark and pale type A spermatogonia in the rhesus monkey (Macaca mulatta) results from proliferation during infantile and juvenile development in a relatively gonadotropin independent manner. Biol Reprod; 2005 Dec;73(6):1109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ad, Ap, and the unclassified A spermatogonia each showed an approximately 4-fold increase over the 5-mo period from birth to infancy, and a similar increase was observed over the 10-mo period between infancy and the juvenile stage of development.
  • This conclusion raises the question of the nature of the signal that arrests the cell cycle of Ad in adult testis.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079304.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U54-HD-08610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


61. Bordini B, Littlejohn E, Rosenfield RL: Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index. J Clin Endocrinol Metab; 2009 Apr;94(4):1168-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: EW girls were similar in age and baseline and ACTH- and GnRHag-stimulated androgen levels to stage-matched NW girls.
  • Overnight FSH patterns paralleled LH patterns, whereas estradiol levels were similar in stage-matched NW and EW groups, differing between stages as expected.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • MedlinePlus Health Information. consumer health - Puberty.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3750-3 [9768696.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):582-90 [9467578.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):891-8 [16728550.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):3786-90 [16895960.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):430-6 [17118995.001]
  • [Cites] Pediatrics. 2007 Mar;119(3):e624-30 [17332182.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):787-96 [17179197.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1347-52 [17264175.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73 [17440019.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2089-96 [18334581.001]
  • [Cites] Pediatrics. 2009 Jan;123(1):84-8 [19117864.001]
  • [Cites] J Pediatr. 2006 Feb;148(2):234-40 [16492435.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):671-80 [10699131.001]
  • [Cites] J Clin Invest. 2000 Mar;105(6):749-55 [10727443.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2122-5 [11000114.001]
  • [Cites] Adv Data. 2000 Jun 8;(314):1-27 [11183293.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):73-9 [11174840.001]
  • [Cites] Pediatrics. 2004 Apr;113(4):911-7 [15060243.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jul;191(1):132-7 [15295353.001]
  • [Cites] J Pediatr. 1971 Jun;78(6):997-1003 [4325224.001]
  • [Cites] N Engl J Med. 1972 Sep 21;287(12):582-6 [4341276.001]
  • [Cites] N Engl J Med. 1973 Aug 9;289(6):282-6 [4352270.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Aug;39(2):293-9 [4370779.001]
  • [Cites] J Clin Endocrinol Metab. 1979 Nov;49(5):730-6 [573761.001]
  • [Cites] Endocrinology. 1981 Apr;108(4):1441-9 [6781875.001]
  • [Cites] N Engl J Med. 1983 Nov 17;309(20):1206-9 [6633568.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Mar;60(3):585-9 [2982902.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Sep;65(3):488-93 [3114303.001]
  • [Cites] Am J Physiol. 1988 Jun;254(6 Pt 1):E786-94 [3377077.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Apr;72(4):773-8 [2005201.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Aug;75(2):442-6 [1639945.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):450-5 [8381802.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):940-9 [8473410.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):119-25 [8027216.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1686-92 [7989476.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1797-805 [7989487.001]
  • [Cites] Endocr Rev. 1995 Jun;16(3):322-53 [7671850.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2980-6 [7559884.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3408-11 [8784105.001]
  • [Cites] Endocrinology. 1996 Nov;137(11):4827-36 [8895353.001]
  • [Cites] Cell Tissue Res. 1997 Jun;288(3):471-83 [9134860.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2248-56 [9215302.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3728-33 [9360532.001]
  • [Cites] Reprod Fertil Dev. 1997;9(5):501-8 [9418979.001]
  • [CommentIn] J Clin Endocrinol Metab. 2009 Apr;94(4):1094-6 [19349476.001]
  • (PMID = 19190110.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK064582; United States / NCRR NIH HHS / RR / UL1 RR024999; United States / PHS HHS / / U54-041859; United States / NIDDK NIH HHS / DK / 5T32DK064582; United States / NCRR NIH HHS / RR / RR-00055; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NICHD NIH HHS / HD / R01 HD039267; United States / NICHD NIH HHS / HD / HD-39267; United States / NCRR NIH HHS / RR / UL1RR024999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ PMC2682481
  •  go-up   go-down


62. Lobo J, Santos F, Grosso D, Lima R, Barreira AL, Leite M Jr, Mafra D, Abdalla DS: Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis. Nephron Clin Pract; 2008;108(4):c298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Oxidative modification of low-density lipoprotein (LDL) has been demonstrated in patients with end-stage renal disease, where it is associated with oxidative stress and plays a key role in the pathogenesis of atherosclerosis.
  • In this context, the generation of minimally oxidized LDL, also called electronegative LDL [LDL(-)], has been associated with active disease, and is a detectable sign of atherogenic tendencies.
  • The purpose of this study was to evaluate serum LDL(-) levels and anti-LDL(-) IgG autoantibodies in end-stage renal disease patients on dialysis, comparing patients on hemodialysis (HD), peritoneal dialysis (PD) and a control group.
  • METHODS: The serum levels of LDL(-) and anti-LDL(-) IgG autoantibodies were measured in 25 patients undergoing HD and 11 patients undergoing PD at the Centro Integrado de Nefrologia, Rio de Janeiro, Brazil.
  • RESULTS: Levels of LDL(-) were higher in HD patients (575.6 +/- 233.1 microg/ml) as compared to PD patients (223.4 +/- 117.5 microg/ml, p < 0.05), which in turn were higher than in the control group (54.9 +/- 33.3 mug/ml, p < 0.01).
  • The anti-LDL(-) IgG autoantibodies were increased in controls (0.36 +/- 0.09 microg/ml) as compared to PD (0.28 +/- 0.12 microg/ml, p < 0.001) and HD patients (0.2 +/- 0.1 microg/ml, p < 0.001).
  • The mean values of total cholesterol and LDL were considered high in the PD group, whereas the mean triceps skin fold was significantly lower in the HD group.
  • LDL(-) may be a useful marker of oxidative stress, and this study suggests that HD patients are more susceptible to cardiovascular risk due to this condition.
  • Moreover, autoantibodies reactive to LDL(-) may have protective effects in chronic kidney disease.
  • [MeSH-minor] Adult. Analysis of Variance. Biomarkers / blood. Body Weights and Measures. Cholesterol / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Nutritional Status. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18434752.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Lipoproteins, LDL; 0 / oxidized low density lipoprotein; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


63. Aziz NA, Pijl H, Frölich M, van der Graaf AW, Roelfsema F, Roos RA: Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J Clin Endocrinol Metab; 2009 Apr;94(4):1223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease.
  • CONTEXT: Huntington's disease (HD) is a fatal hereditary neurodegenerative disorder characterized by motor, cognitive, and behavioral disturbances.
  • Hypothalamic-pituitary-adrenal (HPA) axis dysfunction could contribute to a number of HD signs and symptoms; however, no data are available on cortisol diurnal variations and secretory dynamics in HD patients.
  • OBJECTIVE: The aim of the study was to perform a detailed analysis of HPA axis function in HD patients in relation to clinical signs and symptoms.
  • DESIGN, SETTING, AND PARTICIPANTS: Twenty-four-hour cortisol secretion was studied in eight early-stage, medication-free HD patients and eight age-, sex-, and body mass index-matched controls in a clinical research laboratory.
  • RESULTS: Total cortisol secretion rate and the amplitude of the diurnal cortisol profile were both significantly higher in HD patients compared with controls (3490 +/- 320 vs. 2500 +/- 220 nmol/liter/24 h, P = 0.023; and 111 +/- 14 vs. 64 +/- 8 nmol/liter, P = 0.012, respectively).
  • In HD patients, mean 24-h cortisol levels significantly correlated with total motor score, total functional capacity, as well as body mass index.
  • CONCLUSIONS: HPA axis hyperactivity is an early feature of HD and is likely to result from a disturbed central glucocorticoid feedback due to hypothalamic pathology.
  • HPA axis dysfunction may contribute to some signs and symptoms in HD patients.
  • [MeSH-major] Huntington Disease / physiopathology. Hypothalamo-Hypophyseal System / physiology. Pituitary-Adrenal System / physiology
  • [MeSH-minor] Adult. Behavior. Body Size. Circadian Rhythm. Creatinine / urine. Female. Humans. Hydrocortisone / blood. Male. Middle Aged. Motor Activity. Trinucleotide Repeats


64. Aziz NA, Pijl H, Frölich M, van der Graaf AW, Roelfsema F, Roos RA: Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clin Endocrinol (Oxf); 2010 Aug;73(2):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients.
  • BACKGROUND: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an increased number of CAG repeats in the huntingtin gene.
  • A hallmark of HD is unintended weight loss, the cause of which is unknown.
  • OBJECTIVE: To perform a detailed analysis of adipose tissue function in HD patients as abnormal fat tissue function could contribute to the weight loss.
  • DESIGN, SETTING AND PARTICIPANTS: In a clinical research laboratory, 24-h plasma concentrations of leptin, adiponectin and resistin were studied in nine early-stage, medication-free HD patients and nine age-, gender- and body mass index (BMI)-matched controls.
  • RESULTS: Plasma levels and diurnal rhythmicity of leptin, adiponectin and resistin were not significantly different between HD patients and controls.
  • However, although leptin production increased with higher BMI and fat mass in controls, no such relation was present in HD patients.
  • Both higher pulsatile leptin secretion and higher mean adiponectin levels were associated with a greater degree of motor and functional impairment in HD patients.
  • CONCLUSIONS: CAG-repeat size-dependent interference of the HD mutation with adipose tissue function may contribute to weight loss in HD patients.
  • [MeSH-major] Huntington Disease / genetics. Huntington Disease / metabolism. Leptin / secretion. Trinucleotide Repeat Expansion
  • [MeSH-minor] Adiponectin / blood. Adult. Body Mass Index. Case-Control Studies. Circadian Rhythm / physiology. Female. Humans. Male. Middle Aged. Polymorphism, Genetic / physiology. Resistin / blood. Time Factors

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548952.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin; 0 / Resistin
  •  go-up   go-down


65. Bapat U, Kedlaya PG, Gokulnath: Perceived illness intrusion among patients on hemodialysis. Saudi J Kidney Dis Transpl; 2009 May;20(3):386-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is aimed at understanding the perceived illness intrusion among pa-tients on hemodialysis (HD) and to find the association between illness intrusion and patient demographics as well as duration of dialysis.
  • A cross sectional study involving 90 patients with chronic kidney disease (CKD) stage V, on HD was performed during the period from 2005 to 2006.
  • [MeSH-minor] Activities of Daily Living. Adaptation, Psychological. Adolescent. Adult. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Sickness Impact Profile. Socioeconomic Factors. Surveys and Questionnaires. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414939.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


66. Mann JS, Lowther KM, Mehlmann LM: Reorganization of the endoplasmic reticulum and development of Ca2+ release mechanisms during meiotic maturation of human oocytes. Biol Reprod; 2010 Oct;83(4):578-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immature, germinal vesicle (GV)-stage oocytes had a fine network of ER throughout the cortex and interior, whereas the ER in the in vivo-matured, metaphase II oocytes was organized in large (diameter, ∼2-3 μm) accumulations throughout the cortex and interior.
  • In vivo-matured oocytes contained approximately 1.5-fold the amount of IP(3) receptor protein and released significantly more Ca(2+) in response to IP(3) compared with GV-stage oocytes; however, oocytes matured in vitro did not contain more IP(3) receptor protein or release more Ca(2+) in response to IP(3) compared with GV-stage oocytes.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod. 1992 Aug;7(7):999-1003 [1430145.001]
  • [Cites] Science. 1992 Jul 10;257(5067):251-5 [1321497.001]
  • [Cites] Dev Biol. 1993 Mar;156(1):69-79 [8383620.001]
  • [Cites] Methods Cell Biol. 1993;38:211-20 [8246782.001]
  • [Cites] Hum Reprod. 1993 Dec;8(12):2174-9 [8150920.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):579-87 [8045353.001]
  • [Cites] Development. 1994 Jul;120(7):1851-9 [7924992.001]
  • [Cites] Development. 1994 Dec;120(12):3507-17 [7821218.001]
  • [Cites] Biol Reprod. 1994 Dec;51(6):1088-98 [7888488.001]
  • [Cites] Dev Biol. 1995 Aug;170(2):594-606 [7649386.001]
  • [Cites] Dev Biol. 1995 Aug;170(2):607-15 [7649387.001]
  • [Cites] Development. 1995 Oct;121(10):3259-66 [7588060.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):489-98 [8954721.001]
  • [Cites] Mol Hum Reprod. 1997 Nov;3(11):965-73 [9433922.001]
  • [Cites] Dev Biol. 1998 Nov 1;203(1):221-32 [9806786.001]
  • [Cites] Dev Biol. 1998 Nov 15;203(2):305-22 [9808782.001]
  • [Cites] Mol Hum Reprod. 1999 May;5(5):441-51 [10338367.001]
  • [Cites] Dev Biol. 1999 Jul 15;211(2):157-76 [10395780.001]
  • [Cites] Dev Biol. 1999 Oct 15;214(2):399-411 [10525343.001]
  • [Cites] Hum Reprod. 2005 May;20(5):1349-58 [15695316.001]
  • [Cites] Cloning Stem Cells. 2005;7(4):306-20 [16390266.001]
  • [Cites] Semin Cell Dev Biol. 2006 Apr;17(2):233-43 [16549376.001]
  • [Cites] Dev Biol. 2007 May 1;305(1):133-44 [17368610.001]
  • [Cites] Fertil Steril. 2008 Jan;89(1):84-91 [17462639.001]
  • [Cites] Dev Biol. 2008 Mar 15;315(2):257-79 [18255053.001]
  • [Cites] Reprod Biol. 2008 Mar;8(1):3-22 [18432304.001]
  • [Cites] Dev Biol. 2008 Aug 15;320(2):402-13 [18621368.001]
  • [Cites] Biol Reprod. 2009 Jul;81(1):147-54 [19299317.001]
  • [Cites] Cell Calcium. 2009 Jul;46(1):56-64 [19482353.001]
  • [Cites] Anim Sci J. 2010 Feb;81(1):34-41 [20163670.001]
  • [Cites] Semin Cell Dev Biol. 2006 Apr;17(2):264-73 [16730199.001]
  • [Cites] Development. 2006 Nov;133(21):4355-65 [17038520.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1277-91 [16996508.001]
  • [Cites] Dev Biol. 1999 Nov 15;215(2):431-42 [10545249.001]
  • [Cites] Mol Biol Cell. 2001 Apr;12(4):1103-16 [11294910.001]
  • [Cites] Dev Biol. 2002 May 15;245(2):237-54 [11977978.001]
  • [Cites] Mol Hum Reprod. 2002 Oct;8(10):912-8 [12356940.001]
  • [Cites] Dev Biol. 2002 Oct 15;250(2):280-91 [12376103.001]
  • [Cites] Dev Biol. 2003 Dec 1;264(1):50-63 [14623231.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Jun;16(3):211-9 [15129050.001]
  • [Cites] Dev Biol. 1977 May;57(1):56-74 [863112.001]
  • [Cites] Dev Biol. 1985 Feb;107(2):382-94 [4038667.001]
  • [Cites] Dev Biol. 1988 Nov;130(1):184-97 [3141231.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):1103-10 [2324195.001]
  • [Cites] Dev Biol. 1990 Aug;140(2):300-6 [2373255.001]
  • [Cites] Mol Reprod Dev. 1991 Feb;28(2):183-8 [2007032.001]
  • [Cites] J Physiol. 1992 Sep;455:623-40 [1484365.001]
  • (PMID = 20610804.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD056366; United States / NICHD NIH HHS / HD / HD056366
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inositol 1,4,5-Trisphosphate Receptors; 85166-31-0 / Inositol 1,4,5-Trisphosphate; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2957155
  •  go-up   go-down


67. Masui T, Swift GH, Deering T, Shen C, Coats WS, Long Q, Elsässer HP, Magnuson MA, MacDonald RJ: Replacement of Rbpj with Rbpjl in the PTF1 complex controls the final maturation of pancreatic acinar cells. Gastroenterology; 2010 Jul;139(1):270-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether PTF1-L controls the expression of genes that complete the final stage of acinar differentiation.
  • Whereas PTF1-L bound regulatory sites of genes in normal adult pancreatic cells, the embryonic form (PTF1-J) persisted in the absence of Rbpjl and replaced PTF1-L; the extent of replacement determined gene expression levels.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3752-63 [9851981.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):128-34 [12185368.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50725-33 [12401800.001]
  • [Cites] Curr Biol. 2003 Jan 21;13(2):105-15 [12546783.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1331-47 [14647040.001]
  • [Cites] Eur J Cell Biol. 1999 Feb;78(2):79-90 [10099930.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):75-8 [10615132.001]
  • [Cites] Nat Cell Biol. 2000 Dec;2(12):879-87 [11146651.001]
  • [Cites] Genomics. 2001 Aug;76(1-3):89-98 [11549321.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44018-26 [11562365.001]
  • [Cites] J Biochem. 1999 Oct;126(4):738-47 [10502683.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1301-5 [15543146.001]
  • [Cites] Biochem J. 2005 Feb 1;385(Pt 3):721-7 [15462671.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Nov;289(5):C1169-78 [15987769.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):117-30 [16354684.001]
  • [Cites] Development. 2006 Nov;133(22):4439-50 [17075007.001]
  • [Cites] Sci STKE. 2006 Dec 5;2006(364):cm7 [17148788.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2629-43 [17938243.001]
  • [Cites] Genes Dev. 2008 Jan 15;22(2):166-78 [18198335.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G717-27 [18202109.001]
  • [Cites] World Health Organ Tech Rep Ser. 2007;(935):1-265, back cover [18330140.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5458-68 [18606784.001]
  • [Cites] Differentiation. 2009 Jan;77(1):48-59 [19281764.001]
  • [Cites] Science. 2009 Jun 26;324(5935):1707-10 [19556507.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Oct;41(10):2051-61 [19703661.001]
  • [Cites] Diabetologia. 2004 Apr;47(4):597-613 [15298336.001]
  • [Cites] J Cell Physiol. 1968 Oct;72(2):Suppl 1:1-18 [5693298.001]
  • [Cites] FEBS Lett. 1975 Jul 15;55(1):91-3 [1140432.001]
  • [Cites] J Biol Chem. 1977 Oct 25;252(20):7391-7 [903366.001]
  • [Cites] Biochim Biophys Acta. 1978 Nov 2;513(2):255-67 [718894.001]
  • [Cites] J Cell Biol. 1980 Sep;86(3):784-94 [7410479.001]
  • [Cites] J Biol Chem. 1981 Dec 10;256(23):12367-73 [7028754.001]
  • [Cites] EMBO J. 1984 Jul;3(7):1521-4 [6204864.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Mar 29;127(3):937-42 [3885943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jan;83(1):110-4 [2417232.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2464-76 [2788241.001]
  • [Cites] Genes Dev. 1989 Oct;3(10):1613-24 [2612907.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Jan 15;166(1):358-64 [1689152.001]
  • [Cites] Pancreas. 1995 May;10(4):389-94 [7792296.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4317-29 [8861960.001]
  • [Cites] Mol Cell Biol. 1997 May;17(5):2679-87 [9111338.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):897-903 [9175736.001]
  • [Cites] FEBS Lett. 1998 Nov 6;438(3):165-70 [9827539.001]
  • [Cites] Genome Biol. 2002;3(5):research0023 [12049664.001]
  • (PMID = 20398665.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK061220; United States / NIDDK NIH HHS / DK / U19 DK042502; United States / NIDDK NIH HHS / DK / DK072473; United States / NIDDK NIH HHS / DK / DK061220-07; United States / NICHD NIH HHS / HD / HD060222; United States / NICHD NIH HHS / HD / R21 HD060222-01; United States / NIDDK NIH HHS / DK / U01 DK072473; United States / NIDDK NIH HHS / DK / R01 DK061220-07; United States / NIDDK NIH HHS / DK / DK061220; United States / NIDDK NIH HHS / DK / DK042502; United States / NICHD NIH HHS / HD / HD060222-01; United States / NICHD NIH HHS / HD / R21 HD060222; United States / NIDDK NIH HHS / DK / P01 DK042502
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / RNA, Messenger; 0 / Rbpj protein, mouse; 0 / Transcription Factors; 0 / transcription factor PTF1
  • [Other-IDs] NLM/ NIHMS197646; NLM/ PMC2902682
  •  go-up   go-down


68. Vrabie CD, Petrescu A, Waller M, Cojocaru M, Ciocâlteu A, Dina I: Inflammatory, degenerative and vascular lesions in long-term dialysed patients. Rom J Intern Med; 2009;47(2):149-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The high prevalence of cardiovascular diseases in hemodialysed population suggested that the disease could begin before or during the stage of chronic renal insufficiency.
  • We analyzed the two groups of patients (HD/n=15; the reference group/n=30) regarding immunophenotyping, all types of lymphocytes and interleukin 2 (IL-2).
  • RESULTS: The results have classified the HD patients into three subgroups, depending on the mean of the results from flow cytometry exam, referred to normal values.
  • The assessment of the patients with or without HD to each group was made on the basis of the similar behavior of the markers investigated.
  • The most affected age group in patients with HD was 31-40 years, followed by the age group 41-50 years (26%).
  • One subgroup (A) of HD patients showed the improvement of the total number of T lymphocytes (CD3+/CD19-) after the session, while the total number of B lymphocytes was stable.
  • The third group (C) showed normal values for total T lymphocytes (CD3+/CD19-) before HD, which did not modify significantly after the session.
  • The patients had the same decreased values for B lymphocytes, which have continued to decrease after the HD (7.98%).
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Immunophenotyping. Interleukin-2 Receptor alpha Subunit. Killer Cells, Natural. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067165.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


69. Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, Hirano M, Isaac ND: Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol; 2005 Jul;39(1):133-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel cell lines derived from adult human ventricular cardiomyocytes.
  • Background. - We have established proliferating human cardiomyocyte cell lines derived from non-proliferating primary cultures of adult ventricular heart tissue, using a novel method that may be applicable to many post-mitotic primary cultures.
  • EM ultra structural analysis revealed the presence of myofibrils in the subsarcolemmal region, indicating a precontractile developmental stage.

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913645.001).
  • [ISSN] 0022-2828
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 9951061T; United States / NICHD NIH HHS / HD / HD32062
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Biomarkers
  •  go-up   go-down


70. Brown JV 3rd, Epstein HD, Mattison JN, Micha JP, Rettenmaier MA, Goldstein BH: Occult fallopian tube cancer in a patient with BRCA1 breast cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):749-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, despite the infrequent incidence, emerging evidence suggests that patients who have a deleterious mutation of BRCA1 or -2 mutation may be more vulnerable to developing this disease.
  • A patient with breast carcinoma was initially treated for her disease in 1994.
  • Final pathology revealed occult stage IIC fallopian tube cancer with bilateral ovarian serosal involvement.
  • Although fallopian tube cancer is rare, women who are positive for the BRCA mutation are at greater risk for developing this disease.
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Female. Germ-Line Mutation. Humans. Laparoscopy. Ovarian Neoplasms / surgery. Paclitaxel / administration & dosage. Robotics. Treatment Outcome


71. Garcia-Arocena D, Hagerman PJ: Advances in understanding the molecular basis of FXTAS. Hum Mol Genet; 2010 Apr 15;19(R1):R83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder among carriers of premutation expansions (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene.
  • Although the precise mechanisms involved in rCGG toxicity are unknown, here we discuss the latest advances and models that contribute to the understanding of the molecular basis of FXTAS, and the emerging view of FXTAS as the end-stage of a process that begins in early development.

  • MedlinePlus Health Information. consumer health - Fragile X Syndrome.
  • MedlinePlus Health Information. consumer health - Tremor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] RNA. 2002 Dec;8(12):1482-8 [12515381.001]
  • [Cites] Am J Hum Genet. 2003 Apr;72(4):869-78 [12638084.001]
  • [Cites] Hum Mol Genet. 2003 May 1;12(9):949-59 [12700164.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):119-27 [12898586.001]
  • [Cites] Neuron. 2003 Aug 28;39(5):739-47 [12948442.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6857-75 [12972605.001]
  • [Cites] Nucleic Acids Res. 2003 Nov 1;31(21):6243-8 [14576312.001]
  • [Cites] Arch Neurol. 2008 Apr;65(4):495-8 [18413472.001]
  • [Cites] Cortex. 2008 Jun;44(6):628-36 [18472033.001]
  • [Cites] Am J Med Genet A. 2008 Jun 15;146A(12):1543-6 [18478592.001]
  • [Cites] Hum Reprod. 1998 May;13(5):1184-7 [9647544.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2237-46 [9815620.001]
  • [Cites] Brain Cogn. 2005 Feb;57(1):53-60 [15629215.001]
  • [Cites] Nucleic Acids Res. 2005;33(2):486-96 [15659580.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):888-95 [15964549.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):115-21 [16184602.001]
  • [Cites] Hum Mol Genet. 2005 Dec 1;14(23):3661-71 [16239243.001]
  • [Cites] Brain. 2006 Jan;129(Pt 1):256-71 [16246864.001]
  • [Cites] Brain. 2006 Jan;129(Pt 1):243-55 [16332642.001]
  • [Cites] DNA Repair (Amst). 2006 Feb 3;5(2):286-9 [16344005.001]
  • [Cites] J Clin Psychiatry. 2006 Jan;67(1):87-94 [16426093.001]
  • [Cites] Neuron. 2007 Aug 16;55(4):565-71 [17698010.001]
  • [Cites] Neurology. 2007 Aug 28;69(9):851-9 [17724287.001]
  • [Cites] Hum Reprod. 2005 Feb;20(2):402-12 [15608041.001]
  • [Cites] Behav Brain Res. 2005 Jul 30;162(2):233-9 [15876460.001]
  • [Cites] Mov Disord. 2006 Mar;21(3):420-5 [16250026.001]
  • [Cites] J Dev Behav Pediatr. 2006 Apr;27(2 Suppl):S137-44 [16685180.001]
  • [Cites] J Child Psychol Psychiatry. 2006 Jun;47(6):602-10 [16712637.001]
  • [Cites] Annu Rev Neurosci. 2006;29:259-77 [16776586.001]
  • [Cites] Neurology. 2006 Oct 24;67(8):1426-31 [17060569.001]
  • [Cites] Lancet Neurol. 2007 Jan;6(1):45-55 [17166801.001]
  • [Cites] RNA Biol. 2004 Jul;1(2):103-5 [17179750.001]
  • [Cites] Brain. 2007 Feb;130(Pt 2):404-16 [17166860.001]
  • [Cites] Mov Disord. 2007 Jan 15;22(2):203-6 [17133502.001]
  • [Cites] Neurosci Biobehav Rev. 2007;31(3):315-26 [17097142.001]
  • [Cites] Fertil Steril. 2007 Mar;87(3):456-65 [17074338.001]
  • [Cites] J Urol. 2007 Apr;177(4):1434-7 [17382748.001]
  • [Cites] RNA. 2007 Apr;13(4):555-62 [17283214.001]
  • [Cites] Gene. 2007 Jun 15;395(1-2):125-34 [17442505.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):566-9 [17427188.001]
  • [Cites] Neuron. 2007 Aug 16;55(4):556-64 [17698009.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2326-32 [17635840.001]
  • [Cites] Curr Opin Neurol. 2007 Oct;20(5):572-6 [17885447.001]
  • [Cites] Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140 [17618523.001]
  • [Cites] Exp Cell Res. 2008 Jan 1;314(1):82-91 [17870066.001]
  • [Cites] Arch Neurol. 2008 Jan;65(1):19-25 [18195136.001]
  • [Cites] Neuropsychology. 2008 Jan;22(1):48-60 [18211155.001]
  • [Cites] Am J Med Genet A. 2008 Apr 15;146A(8):1009-16 [18348275.001]
  • [Cites] Nature. 2008 Jun 19;453(7198):1107-11 [18449188.001]
  • [Cites] Psychoneuroendocrinology. 2008 Jul;33(6):863-73 [18472227.001]
  • [Cites] Am J Med Genet A. 2008 Aug 15;146A(16):2060-9 [18570292.001]
  • [Cites] J Med Genet. 2008 Aug;45(8):498-9 [18413371.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1138-44 [18384046.001]
  • [Cites] Neuron. 2008 Oct 23;60(2):201-14 [18957214.001]
  • [Cites] J Neurochem. 2008 Dec;107(6):1671-82 [19014369.001]
  • [Cites] Brain Res. 2009 Feb 9;1253:176-83 [19070606.001]
  • [Cites] Hum Genet. 2004 Apr;114(5):439-47 [14758538.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):1051-6 [15065016.001]
  • [Cites] Nat Rev Neurosci. 2004 Sep;5(9):686-700 [15322527.001]
  • [Cites] Neuropsychologia. 2004;42(14):1934-47 [15381024.001]
  • [Cites] Science. 1991 May 24;252(5009):1179-81 [2031189.001]
  • [Cites] EMBO J. 1992 Feb;11(2):717-24 [1537344.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):331-8 [9218509.001]
  • [Cites] Hum Mol Genet. 2009 Jul 1;18(13):2443-51 [19377084.001]
  • [Cites] J Clin Psychiatry. 2009 Jun;70(6):852-62 [19422761.001]
  • [Cites] EMBO Rep. 2009 Aug;10(8):887-93 [19557000.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):280-4 [18627480.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2009 Sep 5;150B(6):782-98 [19105204.001]
  • [Cites] Eur J Hum Genet. 2009 Oct;17(10):1359-62 [19367323.001]
  • [Cites] Biochem Soc Trans. 2009 Dec;37(Pt 6):1281-6 [19909263.001]
  • [Cites] J Investig Med. 2009 Dec;57(8):837-41 [19574928.001]
  • [Cites] J Investig Med. 2009 Dec;57(8):830-6 [19574929.001]
  • [Cites] Adv Pediatr. 2009;56:165-86 [19968948.001]
  • [Cites] Hum Mol Genet. 2010 Jan 1;19(1):196-208 [19846466.001]
  • [Cites] Hum Mol Genet. 2010 Jan 15;19(2):299-312 [19864489.001]
  • [Cites] Brain Res. 2010 Mar 8;1318:155-66 [20051238.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2010 Apr 5;153B(3):775-85 [19908235.001]
  • [Cites] EMBO J. 2010 Apr 7;29(7):1248-61 [20186122.001]
  • [Cites] Leukemia. 2010 Apr;24(4):679-86 [20130602.001]
  • [Cites] Clin Genet. 2010 Apr;77(4):374-81 [20059484.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):130-9 [18553360.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Nucleic Acids Res. 2000 Sep 1;28(17):3197-205 [10954586.001]
  • [Cites] J Med Genet. 2001 Jul;38(7):453-6 [11432964.001]
  • [Cites] Neurology. 2001 Jul 10;57(1):127-30 [11445641.001]
  • [Cites] Hum Mol Genet. 2001 Jul 1;10(14):1449-54 [11448936.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):215-20 [12065097.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1760-71 [12135967.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1757-66 [12427636.001]
  • (PMID = 20430935.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD040661; United States / NIA NIH HHS / AG / RL1 AG032119; United States / NIDCR NIH HHS / DE / UL1DE19583
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FMR1 protein, human; 139135-51-6 / Fragile X Mental Retardation Protein; 63231-63-0 / RNA
  • [Number-of-references] 90
  • [Other-IDs] NLM/ PMC2875053
  •  go-up   go-down


72. Bergrem H, Gøransson LG, Asmundsson P, Feldt-Rasmussen B, Grønhagen-Riska C, Westberg G: The Nephrocare project: referral, patient case-mix, follow-up and quality of renal care in Nordic renal centres. Scand J Urol Nephrol; 2009;43(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At follow-up, 56% had chronic kidney disease (CKD) not in renal replacement therapy (RRT).
  • Seventeen per cent had haemodialysis (HD), 6% peritoneal dialysis (PD) and 21% a functioning kidney transplant (Tx).
  • In the CKD group, 5.9% were CKD stage 1, 17.6% stage 2, 35.2% stage 3, 25.6% stage 4 and 15.7% stage 5.
  • One-third had known cardiovascular disease, 30% known diabetes, half had a blood pressure >140/90 mmHg and 75% > 130/80 mmHg.
  • One-third of those with known cardiovascular disease were prescribed lipid-lowering therapy and half of those with proteinuria were prescribed an angiotensin-inhibiting drug.
  • The data may serve as a basis for assessing possible change in nephrological practice after the introduction of K/DOQI guidelines and staging of chronic renal disease.
  • [MeSH-minor] Adult. Aged. Chronic Disease. Denmark / epidemiology. Female. Finland / epidemiology. Follow-Up Studies. Humans. Iceland / epidemiology. Male. Middle Aged. Norway / epidemiology. Peritoneal Dialysis. Renal Dialysis. Retrospective Studies. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333821.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Sullivan MA, Rothenberg JL, Vosburg SK, Church SH, Feldman SJ, Epstein EM, Kleber HD, Nunes EV: Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict; 2006 Mar-Apr;15(2):150-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial.
  • An uncontrolled Stage I pilot trial (N = 47) of BNT was conducted.

  • MedlinePlus Health Information. consumer health - Heroin.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NALTREXONE .
  • Hazardous Substances Data Bank. METHADONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595353.001).
  • [ISSN] 1055-0496
  • [Journal-full-title] The American journal on addictions
  • [ISO-abbreviation] Am J Addict
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / DA00288; United States / NIDA NIH HHS / DA / DA00433; United States / NIDA NIH HHS / DA / DA10746
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 5S6W795CQM / Naltrexone; UC6VBE7V1Z / Methadone
  •  go-up   go-down


74. Sahin S, Sahin GM, Ergin H, Kantarci G: The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever. Ren Fail; 2007;29(3):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Familial Mediterranean fever (FMF) is an autosomal recessive disease seen primarily in Sephardic Jews, Turks, and Armenians.
  • The disease manifests as recurrent attacks of fever and serositis.
  • As a result, the best treatment modality of end-stage renal disease (ESRD) in these circumstances still remains unclear.
  • All 40 patients were on renal replacement therapy, 20 on hemodialysis (HD), 20 on peritoneal dialysis (PD).
  • [MeSH-minor] Adult. Biomarkers / blood. Blood Pressure. Creatinine / blood. Dialysis Solutions. Erythropoietin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Recombinant Proteins. Research Design. Retrospective Studies. Surveys and Questionnaires. Treatment Outcome. Turkey. Weight Gain

  • Genetic Alliance. consumer health - Familial Mediterranean fever.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497446.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dialysis Solutions; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; AYI8EX34EU / Creatinine
  •  go-up   go-down


75. Forrest Keenan K, van Teijlingen E, McKee L, Miedzybrodzka Z, Simpson SA: How young people find out about their family history of Huntington's disease. Soc Sci Med; 2009 May;68(10):1892-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How young people find out about their family history of Huntington's disease.
  • Family communication about adult-onset hereditary illness can be problematic, leaving some relatives inadequately informed or ignorant of their risk.
  • Our paper explores young people's experiences of finding out about a family history of the hereditary disorder Huntington's disease (HD).
  • (1) having always been told, (2) gradually told, (3) HD was kept a secret, or (4) HD as a new diagnosis.
  • In particular, the timing and style of disclosure from relatives, and one's stage of awareness, were fundamental in structuring participants' accounts.
  • [MeSH-major] Family Relations. Huntington Disease / genetics. Huntington Disease / psychology. Truth Disclosure
  • [MeSH-minor] Adolescent. Adult. Child. Female. Genetic Predisposition to Disease. Humans. Interviews as Topic. Male. Qualitative Research. Young Adult

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328606.001).
  • [ISSN] 0277-9536
  • [Journal-full-title] Social science & medicine (1982)
  • [ISO-abbreviation] Soc Sci Med
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Thompson R, Emmorey K, Gollan TH: "Tip of the fingers" experiences by deaf signers: insights into the organization of a sign-based lexicon. Psychol Sci; 2005 Nov;16(11):856-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The existence of TOFs supports two-stage retrieval and a division between semantics and phonology in American Sign Language.
  • [MeSH-minor] Adult. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Hearing Disorders and Deafness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16262769.001).
  • [ISSN] 0956-7976
  • [Journal-full-title] Psychological science
  • [ISO-abbreviation] Psychol Sci
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / DC00191; United States / NICHD NIH HHS / HD / R01 HD13249
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


77. Bazzano LA, Gu D, Reynolds K, Chen J, Wu X, Chen CS, Duan X, Chen J, He J: Alcohol consumption and risk of coronary heart disease among Chinese men. Int J Cardiol; 2009 Jun 12;135(1):78-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol consumption and risk of coronary heart disease among Chinese men.
  • BACKGROUND: Observational studies suggest that moderate alcohol consumption may lower risk of myocardial infarction (MI) and coronary heart disease (CHD); yet, evidence for this comes almost entirely from Western populations.
  • After stratification by province to account for multi-stage sampling design and adjustment for age, education, physical activity, cigarette smoking, body mass index, systolic blood pressure, urbanization (urban vs. rural), geographic variation (north vs. south) and history of diabetes, relative risk (95% confidence interval) of MI was 0.93 (0.70-1.24) for participants consuming 1 to 6 drinks/week, 0.66 (0.54-0.82) for those consuming 7 to 34 drinks/week, and 0.58 (0.41-0.81) for those consuming > or = 35 drinks/week (p for linear trend <0.0001) compared to non-drinkers.

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2000 Oct;95(10):1505-23 [11070527.001]
  • [Cites] Ann Intern Med. 2007 Jan 2;146(1):10-9 [17200217.001]
  • [Cites] Alcohol Res Health. 2001;25(4):255-61 [11910702.001]
  • [Cites] Ann Epidemiol. 2002 Nov;12(8):560-7 [12495829.001]
  • [Cites] Circulation. 2004 Sep 7;110(10):1236-44 [15337690.001]
  • [Cites] Br J Addict. 1990 Sep;85(9):1171-5 [2224197.001]
  • [Cites] BMJ. 1991 Aug 3;303(6797):276-82 [1888927.001]
  • [Cites] Ann Epidemiol. 1994 Jan;4(1):46-58 [8205271.001]
  • [Cites] Stroke. 1995 May;26(5):767-73 [7740564.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2285-90 [8964865.001]
  • [Cites] Int J Cardiol. 1995 Nov 10;52(1):39-44 [8707434.001]
  • [Cites] BMJ. 1997 Jan 4;314(7073):18-23 [9001474.001]
  • [Cites] Lancet. 1997 May 24;349(9064):1498-504 [9167458.001]
  • [Cites] Am J Epidemiol. 1998 Jan 1;147(1):59-65 [9440399.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E897-907 [9815011.001]
  • [Cites] Alcohol Health Res World. 1997;21(1):21-9 [15706760.001]
  • [Cites] Am J Prev Med. 2005 May;28(4):369-73 [15831343.001]
  • [Cites] Am J Clin Pathol. 2005 Jun;123 Suppl:S96-105 [16100871.001]
  • [Cites] Am J Public Health. 2005 Sep;95(9):1631-6 [16051938.001]
  • [Cites] Circulation. 2005 Sep 6;112(10):1406-13 [16129796.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1124-34 [16162883.001]
  • [Cites] Am J Cardiol. 2005 Nov 1;96(9):1260-5 [16253594.001]
  • [Cites] Arch Med Res. 2006 Aug;37(6):787-93 [16824940.001]
  • [Cites] Circulation. 2001 Nov 27;104(22):2746-53 [11723030.001]
  • (PMID = 18614248.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017659; United States / NCRR NIH HHS / RR / RR017659-077420; United States / NICHD NIH HHS / HD / K12 HD043451; United States / NICHD NIH HHS / HD / K12-HD43451; United States / NCRR NIH HHS / RR / P20-RR17659; United States / NHLBI NIH HHS / HL / U01 HL072507; United States / NCRR NIH HHS / RR / P20 RR017659-077420; United States / NHLBI NIH HHS / HL / R01 HL068057
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS125586; NLM/ PMC2726155
  •  go-up   go-down


78. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis; 2005 Apr;45(4):658-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study.
  • BACKGROUND: Health-related quality of life (QOL) is an important measure of how disease affects patients' lives.
  • Little is known about QOL in patients with chronic kidney disease (CKD) before renal replacement therapy.
  • SF-36 scores in these patients were compared with those in a prevalent cohort of hemodialysis (HD) patients and healthy controls (both from historical data).
  • RESULTS: Patients with CKD had higher SF-36 scores than a large cohort of HD patients (P < 0.0001 for 8 scales and 2 summary scales), but lower scores than those reported for the US adult population (P < 0.0001 for 7 of 8 scales and 1 of 2 summary scales).
  • Patients with CKD stage 4 had lower QOL scores than patients with CKD stage 5, although differences were not significant.
  • CONCLUSION: SF-36 scores were higher in this CKD cohort compared with HD patients, but lower than in healthy controls.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806468.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Serum Albumin; 11096-26-7 / Erythropoietin
  •  go-up   go-down


79. Miller WB, Bard DE, Pasta DJ, Rodgers JL: Biodemographic modeling of the links between fertility motivation and fertility outcomes in the NLSY79. Demography; 2010 May;47(2):393-414
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conduct a two-stage analysis to examine these inferences in a time-ordered multivariate context.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Demography. 2001 Feb;38(1):29-42 [11227843.001]
  • [Cites] Biodemography Soc Biol. 2010;56(1):1-23 [20463915.001]
  • [Cites] Behav Genet. 2008 Nov;38(6):567-78 [18825497.001]
  • [Cites] J Abnorm Psychol. 2007 May;116(2):236-48 [17516757.001]
  • [Cites] Behav Genet. 2007 Mar;37(2):345-61 [17205393.001]
  • [Cites] Behav Genet. 2007 Mar;37(2):362-75 [17165140.001]
  • [Cites] Int J Androl. 2006 Feb;29(1):46-53 [16466523.001]
  • [Cites] Behav Genet. 2005 Sep;35(5):653-65 [16184491.001]
  • [Cites] J Biosoc Sci. 1999 Jan;31(1):29-41 [10081235.001]
  • [Cites] Evolution. 2001 Feb;55(2):423-35 [11308097.001]
  • [Cites] Soc Biol. 2002 Fall-Winter;49(3-4):218-48 [14652919.001]
  • [Cites] Demography. 1974 Feb;11(1):45-56 [4813038.001]
  • [Cites] Demography. 1977 NOV;14(4):431-53 [913730.001]
  • [Cites] Demography. 1981 Feb;18(1):1-25 [7202782.001]
  • [Cites] Demography. 1982 Aug;19(3):315-34 [7117630.001]
  • [Cites] Demography. 1986 Nov;23(4):579-94 [3803655.001]
  • [Cites] Demography. 1992 May;29(2):265-85 [1607052.001]
  • [Cites] Genet Soc Gen Psychol Monogr. 1994 May;120(2):223-58 [8045374.001]
  • [Cites] J Biosoc Sci. 1995 Oct;27(4):473-87 [7593054.001]
  • [Cites] Soc Biol. 1995 Fall-Winter;42(3-4):185-98 [8738545.001]
  • [Cites] Demography. 2000 Aug;37(3):285-98 [10953804.001]
  • (PMID = 20608103.001).
  • [ISSN] 0070-3370
  • [Journal-full-title] Demography
  • [ISO-abbreviation] Demography
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD043265; United States / NICHD NIH HHS / HD / R01 HD43265
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3000025
  •  go-up   go-down


80. Studinger P, Lénárd Z, Mersich B, Reusz GS, Kollai M: Determinants of baroreflex function in juvenile end-stage renal disease. Kidney Int; 2006 Jun;69(12):2236-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of baroreflex function in juvenile end-stage renal disease.
  • Arterial baroreflex sensitivity (BRS) is markedly reduced in middle-aged patients with end-stage renal disease (ESRD), due to the combined effects of aging, arterial stiffening, and autonomic neuropathy.
  • We studied 42 subjects (9-30 years): 14 patients on maintenance hemodialysis (HD), 14 renal transplant recipients (RT), and 14 healthy control subjects (C).
  • BRS was markedly reduced in HD as compared to C (10.0+/-4.2 vs 25.7+/-5.9 ms/mm Hg); spontaneous indices were reduced to similar extent.
  • Carotid artery stiffness was approximately 50% higher in HD than in C and was inversely related to BRS.
  • Heart rate variability was also compromised in HD, and was directly related to spontaneous indices.
  • Decreased baroreflex function in juvenile HD is partly due to loss of carotid artery elasticity and partly due to impaired heart rate variability.
  • [MeSH-minor] Adolescent. Adult. Aging / physiology. Blood Pressure / physiology. Carotid Arteries / physiopathology. Case-Control Studies. Child. Cross-Sectional Studies. Elasticity. Heart Rate / physiology. Humans. Kidney Transplantation / physiology. Renal Dialysis

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672915.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Kovac J, Buturović-Ponikvar J, Ponikvar R: Vascular access recirculation in hemodialysis patients with two noncuffed, single-lumen, jugular catheters in the same jugular vein. Ther Apher Dial; 2009 Aug;13(4):350-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 11 adult end-stage renal disease patients on chronic hemodialysis (HD), vascular access recirculation was studied using a thermodilution technique during dialysis at our center.
  • During 16 HD procedures, 55 recirculation measurements were taken.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Circulation. Female. Humans. Jugular Veins. Male. Middle Aged. Thermodilution / methods

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695073.001).
  • [ISSN] 1744-9987
  • [Journal-full-title] Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • [ISO-abbreviation] Ther Apher Dial
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


82. Jolous-Jamshidi B, Cromwell HC, McFarland AM, Meserve LA: Perinatal exposure to polychlorinated biphenyls alters social behaviors in rats. Toxicol Lett; 2010 Nov 30;199(2):136-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used a standard habituation-dishabituation paradigm to evaluate juvenile recognition and a social port paradigm to monitor adult social investigation.
  • There was not a concomitant alteration of social investigation in pair-housed PCB exposed animals at this stage of development.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Physiol Behav. 2001 Oct;74(3):363-70 [11714501.001]
  • [Cites] Toxicol Sci. 2002 Jan;65(1):52-61 [11752685.001]
  • [Cites] Physiol Behav. 2002 Apr 15;75(5):689-96 [12020734.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110(10):A593-8 [12361940.001]
  • [Cites] Behav Neurosci. 2004 Apr;118(2):298-305 [15113254.001]
  • [Cites] Toxicology. 2004 Oct 15;203(1-3):99-107 [15363586.001]
  • [Cites] Arch Environ Contam Toxicol. 1975-1976;3(4):479-90 [816261.001]
  • [Cites] Dev Psychobiol. 1982 Jan;15(1):1-8 [7054012.001]
  • [Cites] Physiol Behav. 1986;37(6):869-73 [3786481.001]
  • [Cites] Neurotoxicol Teratol. 1987 Jan-Feb;9(1):51-7 [3627077.001]
  • [Cites] Neurotoxicol Teratol. 1988 May-Jun;10(3):193-7 [3211096.001]
  • [Cites] Dev Psychobiol. 1992 May;25(4):261-74 [1624056.001]
  • [Cites] Eur Neuropsychopharmacol. 1991 May;1(2):123-6 [1821701.001]
  • [Cites] Eur Neuropsychopharmacol. 1991 Dec;1(4):555-60 [1668316.001]
  • [Cites] Bull Environ Contam Toxicol. 1992 May;48(5):715-20 [1324039.001]
  • [Cites] Toxicol Appl Pharmacol. 1995 Nov;135(1):77-88 [7482542.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104 Suppl 2:299-305 [9182036.001]
  • [Cites] Growth Dev Aging. 1996 Autumn-Winter;60(3-4):131-43 [9007564.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Nov;58(3):643-7 [9329053.001]
  • [Cites] Neurotoxicol Teratol. 1997 Sep-Oct;19(5):383-9 [9380005.001]
  • [Cites] Arch Toxicol. 1998 Apr;72(5):314-7 [9630019.001]
  • [Cites] Neurotoxicology. 1998 Aug-Oct;19(4-5):517-25 [9745906.001]
  • [Cites] Dev Psychobiol. 1999 Mar;34(2):129-38 [10086231.001]
  • [Cites] Neurotoxicol Teratol. 1999 Jul-Aug;21(4):435-43 [10440487.001]
  • [Cites] Behav Neurosci. 1999 Jun;113(3):602-11 [10443786.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1999 Jul;23(5):915-28 [10509384.001]
  • [Cites] Toxicol Sci. 2004 Dec;82(2):577-89 [15456922.001]
  • [Cites] Physiol Behav. 2005 Jan 31;84(1):81-6 [15642610.001]
  • [Cites] Neurosci Biobehav Rev. 2005;29(4-5):843-65 [15893378.001]
  • [Cites] Physiol Behav. 2005 Jun 2;85(2):83-91 [15878184.001]
  • [Cites] Toxicol Sci. 2005 Jul;86(1):125-31 [15843507.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):194-201 [16451854.001]
  • [Cites] Neurotoxicol Teratol. 2006 Mar-Apr;28(2):260-77 [16487679.001]
  • [Cites] Rev Environ Health. 2006 Jan-Mar;21(1):1-23 [16700427.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):830-9 [16702358.001]
  • [Cites] Pol J Vet Sci. 2006;9(2):101-8 [16780177.001]
  • [Cites] Neuropharmacology. 2007 Mar;52(3):724-32 [17097693.001]
  • [Cites] Environ Int. 2007 Apr;33(3):397-405 [17270272.001]
  • [Cites] Horm Behav. 2007 Mar;51(3):364-72 [17274994.001]
  • [Cites] Ann Ist Super Sanita. 2006;42(4):410-6 [17361063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7646-51 [17460041.001]
  • [Cites] Tohoku J Exp Med. 2007 Jun;212(2):151-7 [17548959.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):178-86 [17434953.001]
  • [Cites] Physiol Behav. 2007 Aug 15;91(5):658-66 [17498760.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):448-59 [17919130.001]
  • [Cites] Prog Neurobiol. 2008 Jan;84(1):1-24 [18053631.001]
  • [Cites] Rev Environ Health. 2007 Oct-Dec;22(4):313-28 [18351230.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):351-72 [18368561.001]
  • [Cites] Dev Psychobiol. 2008 May;50(4):322-31 [18393285.001]
  • [Cites] Biol Reprod. 2008 Jun;78(6):1091-101 [18305224.001]
  • [Cites] Endocrinology. 2008 Jul;149(7):3256-63 [18356275.001]
  • [Cites] J Neuroendocrinol. 2008 Jun;20(6):858-65 [18601710.001]
  • [Cites] Reprod Toxicol. 2008 Aug;25(4):447-54 [18502095.001]
  • [Cites] Physiol Behav. 2008 Oct 20;95(3):471-5 [18680757.001]
  • [Cites] Environ Health Perspect. 2008 Oct;116(10):1416-22 [18941588.001]
  • [Cites] ILAR J. 2009;50(1):43-50 [19106451.001]
  • [Cites] Behav Brain Res. 2009 Jun 25;200(2):323-35 [19150375.001]
  • [Cites] Stress. 2009 May;12(3):250-8 [18951246.001]
  • [Cites] Neurotoxicology. 2009 May;30(3):331-7 [19442816.001]
  • [Cites] Rev Environ Contam Toxicol. 2009;201:137-58 [19484591.001]
  • [Cites] Physiol Behav. 2009 Aug 4;98(1-2):247-50 [19447123.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Aug 15;239(1):46-54 [19464308.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1173-7 [19563853.001]
  • [Cites] Environ Health Perspect. 2009 Sep;117(9):1454-60 [19750113.001]
  • [Cites] Contemp Top Lab Anim Sci. 2003 Mar;42(2):29-30 [19757622.001]
  • [Cites] Front Neuroendocrinol. 2009 Oct;30(4):497-518 [19341763.001]
  • [Cites] J Comp Neurol. 2009 Nov 10;517(2):156-65 [19731312.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Oct;27(4):286-300 [19953400.001]
  • [Cites] Physiol Behav. 2010 Feb 9;99(2):260-8 [19758571.001]
  • [Cites] Neurotoxicology. 2010 Jan;31(1):17-25 [19854214.001]
  • [Cites] Nature. 2010 Mar 18;464(7287):413-7 [20182426.001]
  • [Cites] Environ Health Perspect. 2010 Jun;118(6):796-802 [20146964.001]
  • [Cites] Environ Health Perspect. 2005 Jun;113(6):700-7 [15929892.001]
  • [Cites] Toxicology. 1999 Oct 29;138(1):11-7 [10566587.001]
  • [Cites] Endocrine. 2001 Mar;14(2):235-46 [11394642.001]
  • [Cites] Ross Fiziol Zh Im I M Sechenova. 2001 Jun;87(6):730-51 [11534200.001]
  • [Cites] Toxicol Ind Health. 2000 Sep;16(7-8):305-33 [11693948.001]
  • (PMID = 20813172.001).
  • [ISSN] 1879-3169
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R03 HD053692
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ NIHMS505413; NLM/ PMC4139010
  •  go-up   go-down


83. Pan Q, Luo X, Chegini N: Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med; 2008 Jan-Feb;12(1):227-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, the expression of a number of miRNAs in myometrium and leiomyoma with their progressive aberrant from normal MSMC into LSMC, transformed and cancerous stage, suggests that miRNAs and their regulation by ovarian steroids play a key role in pathogenesis of leiomyoma through gene expression stability.
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / pharmacology. Estradiol / analogs & derivatives. Estradiol / pharmacology. Estrogens / pharmacology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hormone Antagonists / pharmacology. Humans. Medroxyprogesterone Acetate / pharmacology. Mifepristone / pharmacology. Myocytes, Smooth Muscle / drug effects. Myocytes, Smooth Muscle / metabolism. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod. 2002 Dec;17(12):3213-9 [12456626.001]
  • [Cites] Reprod Biol Endocrinol. 2007;5:34 [17716379.001]
  • [Cites] J Soc Gynecol Investig. 2003 Apr;10(3):161-71 [12699880.001]
  • [Cites] Fertil Steril. 2003 Aug;80(2):266-76 [12909484.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Steroids. 2003 Nov;68(10-13):1019-32 [14667995.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):97-108 [15101043.001]
  • [Cites] Obstet Gynecol. 2004 Jun;103(6):1331-6 [15172874.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1074-96 [15604208.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1097-118 [15604209.001]
  • [Cites] Obstet Gynecol. 2005 Mar;105(3):563-8 [15738025.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] RNA. 2005 Dec;11(12):1753-61 [16314451.001]
  • [Cites] J Soc Gynecol Investig. 2006 Feb;13(2):136-44 [16443508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Nat Cell Biol. 2006 Mar;8(3):278-84 [16489342.001]
  • [Cites] Mol Hum Reprod. 2002 Dec;8(12):1071-8 [12468639.001]
  • [Cites] Fertil Steril. 2000 Jun;73(6):1219-25 [10856486.001]
  • [Cites] Hum Reprod Update. 2001 Jan-Feb;7(1):8-14 [11212080.001]
  • [Cites] Fertil Steril. 2001 Jun;75(6):1198-205 [11384649.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2001 Aug;41(3):295-302 [11592544.001]
  • [Cites] Fertil Steril. 2002 Jul;78(1):114-21 [12095500.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S96-104 [12169536.001]
  • [Cites] Fertil Steril. 2006 Feb;85(2):462-7 [16595228.001]
  • [Cites] Mol Hum Reprod. 2006 Mar;12(3):187-207 [16524927.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6097-104 [16778182.001]
  • [Cites] Methods Enzymol. 2006;411:14-34 [16939783.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 13;349(1):59-68 [16934749.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6156-62 [17028594.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6163-9 [17028595.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6176-87 [17028597.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Steroids. 2006 Nov;71(11-12):960-5 [16935316.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1419-25 [16983573.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):580-7 [17071139.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2135-43 [17135249.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]
  • [Cites] Mol Endocrinol. 2007 May;21(5):1132-47 [17312270.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [RetractionIn] J Cell Mol Med. 2015 Oct;19(10):2512 [26411639.001]
  • [CommentIn] Fed Regist. 2017 Aug 3;82(148):36150-36151 [28857091.001]
  • (PMID = 18182067.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD037432; United States / NICHD NIH HHS / HD / R01 HD037432-07; United States / NICHD NIH HHS / HD / HD37432
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Hormone Antagonists; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / Steroids; 22X328QOC4 / fulvestrant; 320T6RNW1F / Mifepristone; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Other-IDs] NLM/ NIHMS121248; NLM/ PMC2730932
  •  go-up   go-down


84. Toussaint ND, Polkinghorne KR, Kerr PG: Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients. Hemodial Int; 2008 Apr;12(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiovascular (CV) disease is the most common cause of mortality in end-stage kidney disease (ESKD), and arterial stiffness, measured by pulse wave velocity (PWV), is an independent predictor of all-cause and CV mortality.
  • B-type natriuretic peptide (BNP) levels are high in patients with CV disease and ESKD, and increases in BNP may also be a marker of CV risk.
  • We performed a prospective cross-over trial in 19 hemodialysis (HD) patients to assess the impact of regular exercise on surrogate markers of CV risk-arterial compliance and BNP levels.
  • Exercise involved the use of a bicycle ergometer for minimum 30 min at each HD session for 3 months, with a 1-month washout period.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cardiovascular Diseases / blood. Cardiovascular Diseases / etiology. Cardiovascular Diseases / physiopathology. Cardiovascular Diseases / prevention & control. Compliance. Cross-Over Studies. Female. Hemodynamics. Humans. Male. Middle Aged. Prospective Studies. Risk Factors. Vascular Resistance

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394060.001).
  • [ISSN] 1492-7535
  • [Journal-full-title] Hemodialysis international. International Symposium on Home Hemodialysis
  • [ISO-abbreviation] Hemodial Int
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers; 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


85. Yonekura S, Ting CY, Neves G, Hung K, Hsu SN, Chiba A, Chess A, Lee CH: The variable transmembrane domain of Drosophila N-cadherin regulates adhesive activity. Mol Cell Biol; 2006 Sep;26(17):6598-608
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, exon 18b is predominantly expressed during early developmental stages, while exon 18a is prevalent at the late developmental and adult stages.
  • CadN alternative splicing might provide a novel mechanism to fine-tune its adhesive activity at different developmental stages or to restrict the use of high-affinity 18b-type isoforms at the adult stage.

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Struct Biol. 1999 Dec;9(6):696-704 [10607675.001]
  • [Cites] Dev Biol. 1976 Sep;52(2):246-62 [12194436.001]
  • [Cites] Neuron. 2000 Jan;25(1):93-107 [10707975.001]
  • [Cites] Genes Dev. 2000 May 15;14(10):1169-80 [10817752.001]
  • [Cites] Cell. 2000 Jun 9;101(6):671-84 [10892653.001]
  • [Cites] Nat Neurosci. 2000 Oct;3(10):1012-7 [11017174.001]
  • [Cites] Neuron. 2001 May;30(2):437-50 [11395005.001]
  • [Cites] Neurosci Res. 2001 Nov;41(3):207-15 [11672833.001]
  • [Cites] Curr Biol. 2002 Jan 8;12(1):59-63 [11790304.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):313-9 [12551956.001]
  • [Cites] Dev Biol. 2003 Jan 15;253(2):309-23 [12645933.001]
  • [Cites] Curr Opin Struct Biol. 2003 Aug;13(4):412-7 [12948770.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):7965-72 [14585958.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):240-6 [14758360.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):899-906 [15042713.001]
  • [Cites] Neuron. 2004 Apr 8;42(1):63-75 [15066265.001]
  • [Cites] Neuron. 2004 Apr 8;42(1):77-88 [15066266.001]
  • [Cites] Cell. 2004 Sep 3;118(5):619-33 [15339666.001]
  • [Cites] Neuron. 2004 Sep 2;43(5):663-72 [15339648.001]
  • [Cites] Neuron. 2004 Sep 2;43(5):673-86 [15339649.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):219-22 [15473961.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] Dev Biol. 1983 Jan;95(1):249-52 [6402395.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):716-26 [7958432.001]
  • [Cites] Neuron. 1995 Mar;14(3):497-507 [7695896.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] J Cell Biol. 1996 Oct;135(2):487-96 [8896604.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Neuron. 1997 Jul;19(1):77-89 [9247265.001]
  • [Cites] Trends Genet. 1998 Jan;14(1):20-6 [9448462.001]
  • [Cites] J Cell Biol. 1998 Aug 10;142(3):837-46 [9700170.001]
  • [Cites] J Neurobiol. 1998 Dec;37(4):607-21 [9858262.001]
  • [Cites] Nat Struct Biol. 1999 Apr;6(4):310-2 [10201395.001]
  • [Cites] Cell. 1999 Jun 11;97(6):779-90 [10380929.001]
  • [Cites] Neuron. 1999 Jul;23(3):427-30 [10433255.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):171-6 [15640798.001]
  • [Cites] Development. 2005 Mar;132(5):953-63 [15673571.001]
  • [Cites] Nat Neurosci. 2005 Apr;8(4):443-50 [15735641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12944-9 [16123134.001]
  • [Cites] Evol Dev. 2005 Sep-Oct;7(5):376-89 [16174032.001]
  • [Cites] Mol Cell Neurosci. 2006 Jan;31(1):123-30 [16298140.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4704-12 [11741943.001]
  • [Cites] Mol Cell Neurosci. 2002 Mar;19(3):375-88 [11906210.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19600-8 [11916976.001]
  • [Cites] Genomics. 2002 Jun;79(6):849-59 [12036300.001]
  • [Cites] J Mol Biol. 2000 Feb 25;296(3):911-9 [10677291.001]
  • (PMID = 16914742.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD008748; United States / NICHD NIH HHS / HD / HD008748-03; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Protein Isoforms; 0 / RNA, Messenger; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1592838
  •  go-up   go-down


86. Vanasco NB, Lottersberger J, Schmeling MF, Gardner IA, Tarabla HD: [Diagnosis of leptospirosis: evaluation of a solid-phase enzyme immunoassay in different stages of the disease]. Rev Panam Salud Publica; 2007 Jun;21(6):388-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of leptospirosis: evaluation of a solid-phase enzyme immunoassay in different stages of the disease].
  • OBJECTIVE: To develop a solid-phase enzyme immunoassay (ELISA) for genus-specific immunoglobulin G (IgG) determination with leptospirosis and to evaluate the ELISA in different stages of the disease.
  • Each sample was classified, according to the days of the natural history of disease, into one of three stages: first (< 10 days), second (10-25 days), or third (> 25 days).
  • RESULTS: The sensitivity of the evaluated test was much higher in the second stage (93.2%) than in either the first stage (68.1%) or the third stage (78.8%).
  • The specificity increased gradually from 96.3% in the first stage to 100% in the third stage.
  • CONCLUSIONS: Our results indicate that this ELISA test can be a very useful complement to the MAT for the diagnosis of leptospirosis in all the stages and, in particular, in order to diagnose acute disease sooner.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Agglutination Tests / methods. Argentina. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Sensitivity and Specificity. Time Factors

  • Genetic Alliance. consumer health - Leptospirosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761051.001).
  • [ISSN] 1020-4989
  • [Journal-full-title] Revista panamericana de salud pública = Pan American journal of public health
  • [ISO-abbreviation] Rev. Panam. Salud Publica
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Brown TT, Lugar HM, Coalson RS, Miezin FM, Petersen SE, Schlaggar BL: Developmental changes in human cerebral functional organization for word generation. Cereb Cortex; 2005 Mar;15(3):275-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age-related increases in activity were primarily newly recruited, later-stage processing regions, such as in left frontal and left parietal cortex.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Image Interpretation, Computer-Assisted / methods. Language. Magnetic Resonance Imaging / methods. Male. Task Performance and Analysis

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • SciCrunch. SumsDB (Surface Management System Database) and WebCaret Online Visualization: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297366.001).
  • [ISSN] 1047-3211
  • [Journal-full-title] Cerebral cortex (New York, N.Y. : 1991)
  • [ISO-abbreviation] Cereb. Cortex
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD01487; United States / NINDS NIH HHS / NS / NS32979; United States / NINDS NIH HHS / NS / NS41255; United States / NINDS NIH HHS / NS / NS46424
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


88. Selm SB: Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl; 2010 Nov;21(6):1165-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the prevalence of anti-hepatitis C virus (HCV) among the hemodialysis patients and to identify the risk factors of infection in relation to age, sex, blood transfusions, duration of dialysis and primary cause of end stage-kidney disease.
  • We studied 51 patients who were on chronic hemodialysis (HD) at the Al-Gamhourea Teaching Hospital, Aden, Yemen, during Jan-Dec 2007.
  • The anti-HCV antibody prevalence rate among the HD patients was found to be significantly higher than that in the control group (62.7% and 0.8%, respectively).
  • Diabetic nephropathy was a more frequent cause of end-stage renal disease among the anti-HCV antibody-positive patients (30%) than among the anti-HCV antibody-negative patients (19%).
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers / blood. Blood Transfusion / adverse effects. Case-Control Studies. Chi-Square Distribution. Diabetic Nephropathies / epidemiology. Female. Hepatitis C Antibodies / blood. Humans. Male. Middle Aged. Prevalence. Risk Assessment. Risk Factors. Sex Factors. Time Factors. Yemen / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21060200.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hepatitis C Antibodies
  •  go-up   go-down


89. Chiu YL, Chuang YF, Fang KC, Liu SK, Chen HY, Yang JY, Pai MF, Peng YS, Wu KD, Tsai TJ: Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dial Transplant; 2009 Jan;24(1):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the relationship between sleep quality and circulating inflammatory markers has not been previously studied in haemodialysis (HD) patients.
  • METHODS: A total of 114 HD end-stage renal disease patients receiving maintenance HD for >3 months were included in this study.
  • CONCLUSION: Our study demonstrated severe impairment of sleep quality in HD patients and corroborated the role of inflammation in the pathogenesis of sleep disturbance.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / metabolism. Female. Hemoglobins / metabolism. Humans. Interleukin-1beta / blood. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / physiopathology. Kidney Failure, Chronic / therapy. Male. Middle Aged. Phosphates / blood. Sleep / physiology. Sleep Initiation and Maintenance Disorders / blood. Sleep Initiation and Maintenance Disorders / etiology. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664587.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Interleukin-1beta; 0 / Phosphates; 0 / Triglycerides; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


90. Nicholas CR, Haston KM, Pera RA: Intact fetal ovarian cord formation promotes mouse oocyte survival and development. BMC Dev Biol; 2010 Jan 08;10:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mice, surviving perinatal oocytes are enclosed in ovarian follicles for subsequent oocyte development and function in the adult.
  • Because germline cyst and ovarian cord structures are conserved in the human fetal ovary, the identification of genetic components and molecular mechanisms of pre-follicle stage germ and somatic cell structures may be important for understanding human female infertility.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mech Dev. 2000 Mar 1;91(1-2):143-52 [10704839.001]
  • [Cites] Biol Reprod. 2006 Mar;74(3):450-8 [16339043.001]
  • [Cites] Dev Biol. 2000 Oct 15;226(2):209-19 [11023681.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2468-80 [11356696.001]
  • [Cites] Dev Biol. 2001 Jun 15;234(2):339-51 [11397004.001]
  • [Cites] Mol Reprod Dev. 2001 Oct;60(2):225-6 [11553922.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):838-48 [11715050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2890-4 [11867735.001]
  • [Cites] Mech Dev. 2002 Apr;113(1):91-4 [11900980.001]
  • [Cites] Biol Reprod. 2002 Apr;66(4):1134-50 [11906935.001]
  • [Cites] Reproduction. 2002 May;123(5):613-20 [12006089.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2178-80 [12077402.001]
  • [Cites] Reproduction. 2002 Nov;124(5):659-65 [12417004.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):355-62 [12736726.001]
  • [Cites] Development. 2003 Aug;130(16):3663-70 [12835383.001]
  • [Cites] Development. 2003 Dec;130(24):5895-902 [14561636.001]
  • [Cites] Dev Dyn. 2004 Jun;230(2):210-5 [15162500.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Feb 6;1:11 [12646064.001]
  • [Cites] Fertil Steril. 1969 Jan-Feb;20(1):176-89 [5762551.001]
  • [Cites] Am J Obstet Gynecol. 1971 Jul 1;110(5):644-52 [5563226.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1970 Aug 6;259(828):91-101 [4399071.001]
  • [Cites] Nature. 1974 Nov 29;252(5482):396-7 [4431461.001]
  • [Cites] Science. 1981 May 15;212(4496):817-8 [7221564.001]
  • [Cites] Prog Clin Biol Res. 1981;59B:383-92 [7279953.001]
  • [Cites] Development. 1993 Jan;117(1):273-81 [8223251.001]
  • [Cites] Science. 2006 Apr 28;312(5773):596-600 [16574820.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):640-7 [16741957.001]
  • [Cites] Cell Death Differ. 2007 Apr;14(4):671-81 [17082817.001]
  • [Cites] Reproduction. 2007 Aug;134(2):241-52 [17660234.001]
  • [Cites] Hum Reprod. 2008 Jan;23(1):54-61 [18000170.001]
  • [Cites] Hum Mol Genet. 2008 May 1;17(9):1278-91 [18250097.001]
  • [Cites] Hum Mol Genet. 2008 May 1;17(9):1264-77 [18250098.001]
  • [Cites] Dev Dyn. 2008 Dec;237(12):3892-903 [19035350.001]
  • [Cites] Biol Reprod. 2009 Mar;80(3):449-57 [19020301.001]
  • [Cites] Physiol Rev. 1986 Jan;66(1):71-117 [3511481.001]
  • [Cites] Development. 1994 Jan;120(1):135-41 [8119122.001]
  • [Cites] Development. 1994 Apr;120(4):947-56 [7600970.001]
  • [Cites] Development. 1995 Sep;121(9):2937-47 [7555720.001]
  • [Cites] Development. 1996 Dec;122(12):3959-68 [9012516.001]
  • [Cites] Dev Biol. 1997 Jul 1;187(1):107-13 [9224678.001]
  • [Cites] Int J Androl. 1997 Dec;20(6):361-6 [9568529.001]
  • [Cites] Genes Dev. 1998 May 1;12(9):1304-14 [9573047.001]
  • [Cites] Development. 1998 Sep;125(17):3323-8 [9693136.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):405-9 [9989404.001]
  • [Cites] Development. 1999 Apr;126(8):1655-64 [10079228.001]
  • [Cites] Development. 1999 Jul;126(13):2883-90 [10357932.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):257-62 [10370240.001]
  • [Cites] Exp Cell Res. 1961 Sep;24:495-507 [13871511.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):403-16 [15617683.001]
  • [Cites] Dev Biol. 2005 Sep 1;285(1):49-56 [16139834.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5267-77 [16150897.001]
  • [Cites] Apoptosis. 2006 Jan;11(1):25-37 [16374541.001]
  • [Cites] Biol Reprod. 2000 Oct;63(4):1014-23 [10993822.001]
  • (PMID = 20064216.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD047721; United States / NICHD NIH HHS / HD / U54HD055764; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2830955
  •  go-up   go-down


91. Hall JE, Sullivan JP, Richardson GS: Brief wake episodes modulate sleep-inhibited luteinizing hormone secretion in the early follicular phase. J Clin Endocrinol Metab; 2005 Apr;90(4):2050-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the influence of sleep, sleep stage, and time of day on the dynamics of pulsatile LH secretion in the early follicular phase (EFP) of the menstrual cycle, 11 normal women underwent simultaneous polysomnographic monitoring of sleep and measurement of LH in frequent sampling studies during a 40-h protocol that consisted of one night of normal sleep and one night of sleep deprivation followed by an afternoon nap.
  • [MeSH-minor] Adult. Electroencephalography. Female. Humans. Time Factors. Wakefulness / physiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671093.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-15080; United States / NCRR NIH HHS / RR / M01 RR01066; United States / NICHD NIH HHS / HD / U54 HD29164
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


92. Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E, Jennum P, Konofal E, Walker M, Oudiette D, Tabrizi S, Durr A: Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol; 2008 Apr;65(4):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid eye movement sleep disturbances in Huntington disease.
  • BACKGROUND: Sleep disorders including insomnia, movements during sleep, and daytime sleepiness are common but poorly studied in Huntington disease (HD).
  • OBJECTIVE: To evaluate the HD sleep-wake phenotype (including abnormal motor activity during sleep) in patients with various HD stages and the length of CAG repeats.
  • Because a mild hypocretin deficiency has been found in the brains of some patients with HD (hereinafter referred to as HD patients), we also tested the HD patients for narcolepsy.
  • DESIGN AND PATIENTS: Twenty-five HD patients (including 2 premanifest carriers) underwent clinical interview, nighttime video and sleep monitoring, and daytime multiple sleep latency tests.
  • RESULTS: The HD patients had frequent insomnia, earlier sleep onset, lower sleep efficiency, increased stage 1 sleep, delayed and shortened rapid eye movement (REM) sleep, and increased periodic leg movements.
  • Three HD patients (12%) had REM sleep behavior disorders.
  • Reduced REM sleep duration (but not REM sleep behavior disorders) was present in premanifest carriers and patients with very mild HD and worsened with disease severity.
  • In contrast to narcoleptic patients, HD patients had no cataplexy, hypnagogic hallucinations, or sleep paralysis.
  • Four HD patients had abnormally low (< 8 minutes) daytime sleep latencies, but none had multiple sleep-onset REM periods.
  • CONCLUSIONS: The sleep phenotype of HD includes insomnia, advanced sleep phase, periodic leg movements, REM sleep behavior disorders, and reduced REM sleep but not narcolepsy.
  • [MeSH-major] Huntington Disease / diagnosis. REM Sleep Behavior Disorder / diagnosis
  • [MeSH-minor] Adult. Aged. Disease Progression. Disorders of Excessive Somnolence / diagnosis. Disorders of Excessive Somnolence / genetics. Female. Genetic Testing. Heterozygote Detection. Humans. Male. Middle Aged. Narcolepsy / diagnosis. Narcolepsy / genetics. Nocturnal Myoclonus Syndrome / diagnosis. Nocturnal Myoclonus Syndrome / genetics. Phenotype. Polysomnography. Sleep Initiation and Maintenance Disorders / diagnosis. Sleep Initiation and Maintenance Disorders / genetics